TRAIL/Apo2L	B-protein
ligand	I-protein
selectively	O
induces	O
apoptosis	O
and	O
overcomes	O
drug	O
resistance	O
in	O
multiple	O
myeloma	O
:	O
therapeutic	O
applications	O
.	O

Multiple	O
myeloma	O
(	O
MM	O
)	O
remains	O
incurable	O
and	O
novel	O
treatments	O
are	O
urgently	O
needed	O
.	O

Preclinical	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluations	O
were	O
performed	O
to	O
assess	O
the	O
potential	O
therapeutic	O
applications	O
of	O
human	O
recombinant	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-related	I-protein
apoptosis-inducing	I-protein
ligand/Apo2	I-protein
ligand	I-protein
(	O
TRAIL/Apo2L	B-protein
)	O
in	O
MM	O
.	O

TRAIL/Apo2L	B-protein
potently	O
induced	O
apoptosis	O
of	O
MM	B-cell_type
cells	I-cell_type
from	O
patients	O
and	O
the	O
majority	O
of	O
MM	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
including	O
cells	O
sensitive	O
or	O
resistant	O
to	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
doxorubicin	O
(	O
Dox	O
)	O
,	O
melphalan	O
,	O
and	O
mitoxantrone	O
.	O

TRAIL/Apo2L	B-protein
also	O
overcame	O
the	O
survival	O
effect	O
of	O
interleukin	B-protein
6	I-protein
on	O
MM	B-cell_type
cells	I-cell_type
and	O
did	O
not	O
affect	O
the	O
survival	O
of	O
peripheral	B-cell_type
blood	I-cell_type
and	I-cell_type
bone	I-cell_type
marrow	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
purified	B-cell_type
B	I-cell_type
cells	I-cell_type
from	O
healthy	O
donors	O
.	O

The	O
status	O
of	O
the	O
TRAIL	B-protein
receptors	I-protein
(	O
assessed	O
by	O
immunoblotting	O
and	O
flow	O
cytometry	O
)	O
could	O
not	O
predict	O
TRAIL	O
sensitivity	O
of	O
MM	B-cell_type
cells	I-cell_type
.	O

The	O
anti-MM	O
activity	O
of	O
TRAIL/Apo2L	B-protein
was	O
confirmed	O
in	O
nu/xid/bg	O
mice	O
xenografted	O
with	O
human	B-cell_type
MM	I-cell_type
cells	I-cell_type
;	O
TRAIL	B-protein
(	O
500	O
microg	O
intraperitoneally	O
daily	O
for	O
14	O
days	O
)	O
was	O
well	O
tolerated	O
and	O
significantly	O
suppressed	O
the	O
growth	O
of	O
plasmacytomas	B-cell_type
.	O

Dox	O
up-regulated	O
the	O
expression	O
of	O
the	O
TRAIL	B-protein
receptor	I-protein
death	B-protein
receptor	I-protein
5	I-protein
(	O
DR5	B-protein
)	O
and	O
synergistically	O
enhanced	O
the	O
effect	O
of	O
TRAIL	B-protein
not	O
only	O
against	O
MM	B-cell_type
cells	I-cell_type
sensitive	O
to	O
,	O
but	O
also	O
against	O
those	O
resistant	O
to	O
,	O
Dex-	O
or	O
Dox-induced	O
apoptosis	O
.	O

Nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
inhibitors	O
,	O
such	O
as	O
SN50	O
(	O
a	O
cell-permeable	O
inhibitor	O
of	O
the	O
nuclear	O
translocation	O
and	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-protein
)	O
or	O
the	O
proteasome	O
inhibitor	O
PS-341	O
,	O
enhanced	O
the	O
proapoptotic	O
activity	O
of	O
TRAIL/Apo2L	B-protein
against	O
TRAIL-sensitive	B-cell_type
MM	I-cell_type
cells	I-cell_type
,	O
whereas	O
SN50	O
reversed	O
the	O
TRAIL	O
resistance	O
of	O
ARH-77	B-cell_type
and	I-cell_type
IM-9	I-cell_type
MM	I-cell_type
cells	I-cell_type
.	O

Importantly	O
,	O
normal	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
were	O
not	O
sensitized	O
to	O
TRAIL	B-protein
by	O
either	O
Dox	O
,	O
SN50	O
,	O
or	O
PS-341	O
.	O

These	O
preclinical	O
studies	O
suggest	O
that	O
TRAIL/Apo2L	B-protein
can	O
overcome	O
conventional	O
drug	O
resistance	O
and	O
provide	O
the	O
basis	O
for	O
clinical	O
trials	O
of	O
TRAIL	B-protein
-based	O
treatment	O
regimens	O
to	O
improve	O
outcome	O
in	O
patients	O
with	O
MM	O
.	O

(	O
Blood.	O
2001	O
;	O
98	O
:	O
795-804	O
)	O

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

NEOPLASIA	NULL
TRAIL	NULL
ligand	NULL
selectively	NULL
induces	NULL
apoptosis	NULL
and	NULL
overcomes	NULL
drug	NULL
resistance	NULL
in	NULL
multiple	NULL
myeloma	NULL
:	NULL
therapeutic	NULL
applications	NULL
Constantine	NULL
S.	NULL
Mitsiades	NULL
,	NULL
Steven	NULL
P.	NULL
Treon	NULL
,	NULL
Nicholas	NULL
Mitsiades	NULL
,	NULL
Yoshihito	NULL
Shima	NULL
,	NULL
Paul	NULL
Richardson	NULL
,	NULL
Robert	NULL
Schlossman	NULL
,	NULL
Teru	NULL
Hideshima	NULL
,	NULL
and	NULL
Kenneth	NULL
C.	NULL
Anderson	NULL
Multiple	NULL
myeloma	NULL
(	NULL
MM	NULL
)	NULL
remains	NULL
incurable	NULL
and	NULL
novel	NULL
treatments	NULL
are	NULL
urgently	NULL
needed	NULL
.	NULL

Preclinical	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
evaluations	NULL
were	NULL
performed	NULL
to	NULL
assess	NULL
the	NULL
potential	NULL
therapeutic	NULL
applications	NULL
of	NULL
human	NULL
recombinant	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
-related	NULL
apoptosis-inducing	NULL
ligand/	NULL
Apo	NULL
?	NULL

ligand	NULL
(	NULL
TRAIL/Apo2L	NULL
)	NULL
in	NULL
MM	NULL
.	NULL

TRAIL	NULL
Apo2L	NULL
potently	NULL
induced	NULL
apoptosis	NULL
of	NULL
MM	NULL
cells	NULL
from	NULL
patients	NULL
and	NULL
the	NULL
majority	NULL
of	NULL
MM	NULL
cell	NULL
lines	NULL
,	NULL
including	NULL
cells	NULL
sensitive	NULL
or	NULL
resistant	NULL
to	NULL
dexamethasone	NULL
(	NULL
Dex	NULL
)	NULL
,	NULL
doxorubicin	NULL
(	NULL
Dox	NULL
)	NULL
,	NULL
melphalan	NULL
,	NULL
and	NULL
mitoxantrone	NULL
.	NULL

TRAIL/Apo2L	NULL
also	NULL
overcame	NULL
the	NULL
survival	NULL
effect	NULL
of	NULL
interleukin	NULL
6	NULL
on	NULL
MM	NULL
cells	NULL
and	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
survival	NULL
of	NULL
peripheral	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
mononuclear	NULL
cells	NULL
and	NULL
purified	NULL
B	NULL
cells	NULL
from	NULL
healthy	NULL
donors	NULL
.	NULL

The	NULL
status	NULL
of	NULL
the	NULL
TRAIL	NULL
receptors	NULL
(	NULL
assessed	NULL
by	NULL
immunoblotting	NULL
and	NULL
flow	NULL
cytometry	NULL
)	NULL
could	NULL
not	NULL
predict	NULL
TRAIL	NULL
sensitivity	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

The	NULL
anti-MM	NULL
activity	NULL
of	NULL
TRAIL/Apo2L	NULL
was	NULL
confirmed	NULL
in	NULL
nu/xid/bg	NULL
mice	NULL
xenografted	NULL
with	NULL
human	NULL
MM	NULL
cells	NULL
;	NULL
TRAIL	NULL
(	NULL
500	NULL
g	NULL
intraperitoneally	NULL
daily	NULL
for	NULL
14	NULL
days	NULL
)	NULL
was	NULL
well	NULL
tolerated	NULL
and	NULL
significantly	NULL
suppressed	NULL
the	NULL
growth	NULL
of	NULL
plasmacytomas	NULL
.	NULL

Dox	NULL
up-regulated	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
TRAIL	NULL
receptor	NULL
death	NULL
receptor	NULL
5	NULL
(	NULL
DR5	NULL
)	NULL
and	NULL
synergistically	NULL
enhanced	NULL
the	NULL
effect	NULL
of	NULL
TRAIL	NULL
not	NULL
only	NULL
against	NULL
MM	NULL
cells	NULL
sensitive	NULL
to	NULL
,	NULL
but	NULL
also	NULL
against	NULL
those	NULL
resistant	NULL
to	NULL
,	NULL
Dex-	NULL
or	NULL
Dox-induced	NULL
apoptosis	NULL
.	NULL

Nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-kB	NULL
inhibitors	NULL
,	NULL
such	NULL
as	NULL
SN50	NULL
(	NULL
a	NULL
cell-permeable	NULL
inhibitor	NULL
of	NULL
the	NULL
nuclear	NULL
translocation	NULL
and	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
or	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
PS-341	NULL
,	NULL
enhanced	NULL
the	NULL
proapoptotic	NULL
activity	NULL
of	NULL
TRAIL/Apo2L	NULL
against	NULL
TRAIL-sensitive	NULL
MM	NULL
cells	NULL
,	NULL
whereas	NULL
SN5O0	NULL
reversed	NULL
the	NULL
TRAIL	NULL
resistance	NULL
of	NULL
ARH-77	NULL
and	NULL
IM-9	NULL
MM	NULL
cells	NULL
.	NULL

Importantly	NULL
,	NULL
normal	NULL
B	NULL
lymphocytes	NULL
were	NULL
not	NULL
sensitized	NULL
to	NULL
TRAIL	NULL
by	NULL
either	NULL
Dox	NULL
,	NULL
SN50	NULL
,	NULL
or	NULL
PS-341	NULL
.	NULL

These	NULL
preclinical	NULL
studies	NULL
suggest	NULL
that	NULL
TRAIL/Apo2L	NULL
can	NULL
overcome	NULL
conventional	NULL
drug	NULL
resistance	NULL
and	NULL
provide	NULL
the	NULL
basis	NULL
for	NULL
clinical	NULL
trials	NULL
of	NULL
TRAIL-based	NULL
treatment	NULL
regimens	NULL
to	NULL
improve	NULL
outcome	NULL
in	NULL
patients	NULL
with	NULL
MM	NULL
.	NULL

(	NULL
Blood	NULL
.	NULL

2001	NULL
;	NULL
98:795-804	NULL
)	NULL
©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
Introduction	NULL
The	NULL
uniformly	NULL
fatal	NULL
outcome	NULL
of	NULL
multiple	NULL
myeloma	NULL
(	NULL
MM	NULL
)	NULL
!	NULL

warrants	NULL
the	NULL
development	NULL
of	NULL
novel	NULL
biologically	NULL
based	NULL
treatment	NULL
strategies	NULL
that	NULL
selectively	NULL
induce	NULL
apoptosis	NULL
of	NULL
malignant	NULL
plasma	NULL
cells	NULL
.	NULL

One	NULL
such	NULL
approach	NULL
involves	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
INF	NULL
)	NULL
-related	NULL
apoptosis-inducing	NULL
ligand	NULL
or	NULL
Apo2	NULL
ligand	NULL
(	NULL
TRAIL/Apo2L	NULL
)	NULL
,	NULL
a	NULL
member	NULL
of	NULL
a	NULL
superfamily	NULL
of	NULL
cell	NULL
death-inducing	NULL
ligands	NULL
that	NULL
also	NULL
includes	NULL
TNF-	NULL
«	NULL
and	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL	NULL
or	NULL
CD95L	NULL
)	NULL
.A	NULL
TRAIL/Apo2L	NULL
induces	NULL
apoptosis	NULL
of	NULL
malignant	NULL
cells	NULL
by	NULL
interacting	NULL
with	NULL
a	NULL
complex	NULL
system	NULL
of	NULL
cell	NULL
surface	NULL
receptors	NULL
,	NULL
including	NULL
the	NULL
death	NULL
signal-transducing	NULL
receptors	NULL
DR4	NULL
and	NULL
DR5	NULL
.	NULL

These	NULL
2	NULL
receptors	NULL
transmit	NULL
a	NULL
proapoptotic	NULL
signal	NULL
via	NULL
interaction	NULL
of	NULL
their	NULL
intracellular	NULL
death	NULL
domains	NULL
with	NULL
adaptor	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
,	NULL
which	NULL
are	NULL
not	NULL
well	NULL
characterized	NULL
.	NULL

The	NULL
death	NULL
effector	NULL
domain	NULL
of	NULL
these	NULL
adaptor	NULL
(	NULL
s	NULL
)	NULL
constitutively	NULL
bind	NULL
(	NULL
s	NULL
)	NULL
to	NULL
caspases	NULL
,	NULL
initiating	NULL
a	NULL
cascade	NULL
of	NULL
proteolytic	NULL
activation	NULL
of	NULL
downstream	NULL
caspases	NULL
and	NULL
apoptosis	NULL
.	NULL
``	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
DR4	NULL
and	NULL
DR5	NULL
receptors	NULL
,	NULL
2	NULL
other	NULL
cell	NULL
surface	NULL
TRAIL	NULL
receptors	NULL
(	NULL
DcR1	NULL
,	NULL
DcR2	NULL
)	NULL
lack	NULL
a	NULL
functional	NULL
death	NULL
domain	NULL
and	NULL
can	NULL
not	NULL
transduce	NULL
a	NULL
proapoptotic	NULL
signal	NULL
;	NULL
hence	NULL
,	NULL
they	NULL
are	NULL
considered	NULL
``	NULL
decoy	NULL
receptors	NULL
,	NULL
``	NULL
which	NULL
compete	NULL
with	NULL
DR4	NULL
and	NULL
DR5	NULL
for	NULL
cell	NULL
surface	NULL
TRAIL	NULL
binding	NULL
.	NULL

This	NULL
complex	NULL
system	NULL
of	NULL
TRAIL	NULL
receptors	NULL
,	NULL
and	NULL
in	NULL
particular	NULL
the	NULL
expression	NULL
of	NULL
decoy	NULL
receptors	NULL
on	NULL
normal	NULL
cells	NULL
,	NULL
was	NULL
initially	NULL
postulated	NULL
to	NULL
be	NULL
the	NULL
basis	NULL
for	NULL
the	NULL
specificity	NULL
of	NULL
TRAIL	NULL
's	NULL
proapoptotic	NULL
action	NULL
against	NULL
cancer	NULL
cells	NULL
.	NULL
``	NULL

TRAIL/Apo2L	NULL
induces	NULL
apoptosis	NULL
in	NULL
tumor	NULL
cells	NULL
of	NULL
diverse	NULL
origins,4*	NULL
``	NULL
``	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
various	NULL
in	NULL
vivo	NULL
tumor	NULL
models	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
TRAIL/Apo2L	NULL
is	NULL
not	NULL
toxic	NULL
to	NULL
most	NULL
normal	NULL
human	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
``	NULL
or	NULL
to	NULL
TRAIL-treated	NULL
animals	NULL
,	NULL
``	NULL
``	NULL
even	NULL
though	NULL
the	NULL
messenger	NULL
RNAs	NULL
for	NULL
TRAIL	NULL
receptors	NULL
are	NULL
expressed	NULL
in	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
normal	NULL
tissues	NULL
.	NULL
``	NULL

''	NULL
This	NULL
favorable	NULL
profile	NULL
of	NULL
TRAIL	NULL
in	NULL
various	NULL
tumor	NULL
models	NULL
prompted	NULL
us	NULL
to	NULL
investigate	NULL
whether	NULL
this	NULL
death	NULL
ligand	NULL
is	NULL
active	NULL
against	NULL
MM	NULL
cells	NULL
.	NULL
``	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
show	NULL
that	NULL
TRAIL/ApoZL	NULL
selectively	NULL
induces	NULL
apoptosis	NULL
of	NULL
human	NULL
MM	NULL
cells	NULL
,	NULL
including	NULL
MM	NULL
cell	NULL
lines	NULL
,	NULL
both	NULL
sensitive	NULL
and	NULL
resistant	NULL
to	NULL
dexamethasone	NULL
(	NULL
Dex	NULL
)	NULL
and	NULL
chemotherapy	NULL
,	NULL
as	NULL
well	NULL
as	NULL
patient	NULL
MM	NULL
cells	NULL
,	NULL
and	NULL
exhibits	NULL
in	NULL
vivo	NULL
anti-MM	NULL
activity	NULL
in	NULL
mice	NULL
xenografted	NULL
with	NULL
human	NULL
plasmacytomas	NULL
.	NULL

Moreover	NULL
,	NULL
doxorubicin	NULL
(	NULL
Dox	NULL
)	NULL
and	NULL
agents	NULL
that	NULL
inhibit	NULL
NF-kB	NULL
augment	NULL
the	NULL
activity	NULL
of	NULL
TRAIL/Apo2L	NULL
in	NULL
MM	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
.	NULL

These	NULL
studies	NULL
provide	NULL
the	NULL
rationale	NULL
for	NULL
use	NULL
of	NULL
TRAIL/ApoZL	NULL
as	NULL
a	NULL
novel	NULL
therapeutic	NULL
agent	NULL
in	NULL
MM	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
MM	NULL
cell	NULL
lines	NULL
and	NULL
MM	NULL
patient	NULL
cells	NULL
The	NULL
Dex-sensitive	NULL
MM-18	NULL
and	NULL
Dex-resistant	NULL
MM-1R	NULL
human	NULL
MM	NULL
cell	NULL
lines	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Steven	NULL
Rosen	NULL
(	NULL
Northwestern	NULL
University	NULL
,	NULL
From	NULL
the	NULL
Jerome	NULL
Lipper	NULL
Multiple	NULL
Myeloma	NULL
Center	NULL
,	NULL
Department	NULL
of	NULL
Adult	NULL
Oncology	NULL
,	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
.	NULL

Submitted	NULL
October	NULL
16	NULL
,	NULL
2000	NULL
;	NULL
accepted	NULL
March	NULL
18	NULL
,	NULL
2001	NULL
.	NULL

Supported	NULL
by	NULL
the	NULL
Laurie	NULL
Strauss	NULL
Leukemia	NULL
Foundation	NULL
(	NULL
S.P.T	NULL
.	NULL

and	NULL
N.M.	NULL
)	NULL
,	NULL
the	NULL
International	NULL
Myeloma	NULL
Foundation	NULL
(	NULL
S.P.T	NULL
.	NULL
)	NULL

,	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Clinical	NULL
Oncology	NULL
Young	NULL
Investigator	NULL
Award	NULL
(	NULL
S.P.T	NULL
.	NULL
)	NULL

,	NULL
the	NULL
Multiple	NULL
Myeloma	NULL
Research	NULL
Foundation	NULL
(	NULL
S.P.T	NULL
.	NULL
)	NULL

,	NULL
and	NULL
the	NULL
Doris	NULL
Duke	NULL
Distinguished	NULL
Clinical	NULL
Research	NULL
BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
Scientist	NULL
Award	NULL
(	NULL
K.C.A	NULL
.	NULL
)	NULL

.	NULL

Reprints	NULL
:	NULL
Kenneth	NULL
C.	NULL
Anderson	NULL
,	NULL
Dept	NULL
of	NULL
Adult	NULL
Oncology	NULL
,	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
44	NULL
Binney	NULL
St	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
;	NULL
e-mail	NULL
:	NULL
kenneth_anderson	NULL
@	NULL
difci.harvard.edu	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

Therefore	NULL
,	NULL
and	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
,	NULL
this	NULL
article	NULL
is	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
.	NULL

©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
795	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

796	NULL
_	NULL
MITSIADES	NULL
etal	NULL
Chicago	NULL
,	NULL
IL	NULL
)	NULL
;	NULL
RPMI-8226/8	NULL
cells	NULL
and	NULL
their	NULL
doxorubicin-	NULL
(	NULL
Dox6	NULL
,	NULL
Dox40	NULL
)	NULL
,	NULL
melphalan	NULL
(	NULL
LR5	NULL
)	NULL
-	NULL
,	NULL
and	NULL
mitoxantrone	NULL
(	NULL
MR20	NULL
)	NULL
-resistant	NULL
sublines	NULL
by	NULL
Dr	NULL
William	NULL
Dalton	NULL
(	NULL
Lee	NULL
Moffit	NULL
Cancer	NULL
Center	NULL
,	NULL
Tampa	NULL
,	NULL
FL	NULL
)	NULL
;	NULL
OCI-My-5	NULL
cells	NULL
by	NULL
Dr	NULL
H.	NULL
A.	NULL
Messner	NULL
(	NULL
Ontario	NULL
Cancer	NULL
Institute	NULL
,	NULL
ON	NULL
,	NULL
Canada	NULL
)	NULL
;	NULL
S6B45	NULL
cells	NULL
by	NULL
Dr	NULL
T.	NULL
Kishimoto	NULL
(	NULL
Osaka	NULL
University	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
;	NULL
ARP-1	NULL
cells	NULL
by	NULL
Dr	NULL
O.	NULL
Bajenova	NULL
(	NULL
Boston	NULL
University	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
;	NULL
and	NULL
DHL4	NULL
and	NULL
DHL	NULL
10	NULL
diffuse	NULL
large	NULL
B-cell	NULL
non-Hodgkin	NULL
lymphoma	NULL
(	NULL
NHL	NULL
)	NULL
lines	NULL
by	NULL
Dr	NULL
Margaret	NULL
Shipp	NULL
(	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

U266	NULL
,	NULL
ARH-77	NULL
,	NULL
HS-Sultan	NULL
,	NULL
and	NULL
IM-9	NULL
human	NULL
MM	NULL
cell	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
MM-AS	NULL
and	NULL
MM-SV	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
from	NULL
samples	NULL
from	NULL
2	NULL
MM	NULL
patients	NULL
.	NULL

'*	NULL
Fresh	NULL
MM	NULL
cells	NULL
from	NULL
5	NULL
patients	NULL
,	NULL
including	NULL
bone	NULL
marrow	NULL
mononuclear	NULL
cells	NULL
(	NULL
BMMCs	NULL
)	NULL
of	NULL
3	NULL
patients	NULL
and	NULL
leukemic	NULL
plasma	NULL
cells	NULL
from	NULL
2	NULL
patients	NULL
,	NULL
were	NULL
initially	NULL
processed	NULL
by	NULL
Ficoll	NULL
density	NULL
centrifugation	NULL
and	NULL
incubated	NULL
with	NULL
TRAIL	NULL
,	NULL
either	NULL
in	NULL
unpurified	NULL
form	NULL
or	NULL
following	NULL
tumor	NULL
cell	NULL
isolation	NULL
by	NULL
using	NULL
an	NULL
EPICS	NULL
cell	NULL
sorter	NULL
(	NULL
Coulter	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Tumor	NULL
cell	NULL
sorting	NULL
from	NULL
the	NULL
2	NULL
plasma	NULL
cell	NULL
leukemic	NULL
samples	NULL
was	NULL
performed	NULL
following	NULL
staining	NULL
with	NULL
anti-CD38	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
;	NULL
Beckman-Coulter	NULL
,	NULL
Miami	NULL
,	NULL
FL	NULL
)	NULL
and	NULL
anti-CD45RA-phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
mAb	NULL
(	NULL
Beckman-Coulter/Immunotech	NULL
,	NULL
Miami	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Tumor	NULL
cells	NULL
from	NULL
the	NULL
BMMCs	NULL
of	NULL
1	NULL
MM	NULL
patient	NULL
were	NULL
sorted	NULL
after	NULL
staining	NULL
for	NULL
anti-CD138-PE	NULL
mAb	NULL
(	NULL
Immunotech	NULL
,	NULL
Westbrook	NULL
,	NULL
ME	NULL
)	NULL
and	NULL
anti-CD38	NULL
FITC	NULL
mAb	NULL
.	NULL

Two	NULL
MM	NULL
BMMC	NULL
samples	NULL
were	NULL
used	NULL
in	NULL
our	NULL
studies	NULL
in	NULL
unpurified	NULL
form	NULL
.	NULL

All	NULL
sorted	NULL
tumor	NULL
cell	NULL
samples	NULL
had	NULL
more	NULL
than	NULL
95	NULL
%	NULL
purity	NULL
in	NULL
CD38*	NULL
CD138+*	NULL
or	NULL
CD38+*	NULL
CD4SRA~	NULL
cells	NULL
.	NULL

Immediately	NULL
prior	NULL
to	NULL
TRAIL/Apo2L	NULL
treatment	NULL
studies	NULL
,	NULL
all	NULL
tumor	NULL
samples	NULL
were	NULL
confirmed	NULL
to	NULL
have	NULL
more	NULL
than	NULL
95	NULL
%	NULL
viability	NULL
,	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
assay	NULL
.	NULL

All	NULL
MM	NULL
cell	NULL
lines	NULL
and	NULL
patient	NULL
MM	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco	NULL
Laboratories	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
charcoal	NULL
dextran-treated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
;	NULL
Hyclone	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
as	NULL
well	NULL
as	NULL
L-glutamine	NULL
,	NULL
penicillin	NULL
,	NULL
and	NULL
streptomycin	NULL
(	NULL
Gibco	NULL
Laboratories	NULL
)	NULL
.	NULL

Reagents	NULL
Recombinant	NULL
human	NULL
TRAIL	NULL
was	NULL
obtained	NULL
from	NULL
Immunex	NULL
Corporation	NULL
(	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
,	NULL
in	NULL
a	NULL
leucine	NULL
zipper	NULL
(	NULL
LZ	NULL
)	NULL
form	NULL
.	NULL

*	NULL
Goat	NULL
polyclonal	NULL
antibodies	NULL
for	NULL
human	NULL
DR4	NULL
,	NULL
DR5	NULL
,	NULL
and	NULL
DcRI1	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
mAbs	NULL
for	NULL
DR4	NULL
,	NULL
DR5	NULL
,	NULL
DcR1	NULL
,	NULL
and	NULL
DcR2	NULL
were	NULL
from	NULL
Genentech	NULL
(	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
mouse	NULL
MsIgG1	NULL
and	NULL
MsIgG2b	NULL
isotype	NULL
controls	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
annexin	NULL
V-PI	NULL
early	NULL
apoptosis	NULL
detection	NULL
kit	NULL
,	NULL
the	NULL
Apo2.7-PE	NULL
mAb	NULL
,	NULL
and	NULL
the	NULL
2H4	NULL
antihuman	NULL
CDA4SRA-FITC	NULL
mAb	NULL
from	NULL
Beckman	NULL
Coulter/Immunotech	NULL
;	NULL
interleukin	NULL
6	NULL
(	NULL
IL-6	NULL
)	NULL
,	NULL
goat	NULL
antihuman	NULL
DR4	NULL
,	NULL
DR5	NULL
,	NULL
and	NULL
DcR2	NULL
polyclonal	NULL
antibodies	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
(	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
;	NULL
antihuman	NULL
DcR2	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
from	NULL
Imgenex	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
rabbit	NULL
antihuman	NULL
DcR1	NULL
polyclonal	NULL
antibody	NULL
from	NULL
Affinity	NULL
Bioreagents	NULL
(	NULL
Golden	NULL
,	NULL
CO	NULL
)	NULL
;	NULL
goat	NULL
antimouse	NULL
IgG	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
;	NULL
fragment	NULL
,	NULL
donkey	NULL
antigoat	NULL
IgG	NULL
FITC-conjugated	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
;	NULL
fragment	NULL
,	NULL
and	NULL
donkey	NULL
antirabbit	NULL
IgG	NULL
FITC-conjugated	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragment	NULL
from	NULL
Jackson	NULL
Immunoresearch	NULL
Laboratories	NULL
(	NULL
West	NULL
Grove	NULL
,	NULL
PA	NULL
)	NULL
;	NULL
MTT	NULL
and	NULL
doxorubicin	NULL
from	NULL
Sigma	NULL
Chemical	NULL
(	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
;	NULL
the	NULL
inhibitory	NULL
peptide	NULL
SN50	NULL
and	NULL
its	NULL
mutant	NULL
control	NULL
peptide	NULL
SNSOM	NULL
from	NULL
BIOMOL	NULL
(	NULL
Plymouth	NULL
Meeting	NULL
,	NULL
PA	NULL
)	NULL
;	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
PS-341	NULL
from	NULL
Millenium	NULL
Pharmaceuticals	NULL
(	NULL
Cam-bridge	NULL
,	NULL
MA	NULL
)	NULL
;	NULL
complete-TM	NULL
mixture	NULL
of	NULL
proteinase	NULL
inhibitors	NULL
,	NULL
Ig-free	NULL
normal	NULL
horse	NULL
serum	NULL
and	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
from	NULL
Life	NULL
Technologies	NULL
(	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
;	NULL
and	NULL
the	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
)	NULL
kit	NULL
,	NULL
which	NULL
includes	NULL
the	NULL
peroxidase-labeled	NULL
antimouse	NULL
and	NULL
antirabbit	NULL
secondary	NULL
antibodies	NULL
,	NULL
from	NULL
Amersham	NULL
(	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
TRAIL	NULL
receptor	NULL
status	NULL
by	NULL
immunoblotting	NULL
Cell	NULL
extracts	NULL
from	NULL
10	NULL
MM	NULL
cell	NULL
lines	NULL
(	NULL
ARH-77	NULL
,	NULL
OCI-My-5	NULL
,	NULL
RPMI-8226/8	NULL
,	NULL
$	NULL
6B45	NULL
,	NULL
U266	NULL
,	NULL
IM-9	NULL
,	NULL
HS-Sultan	NULL
,	NULL
MM-1S	NULL
,	NULL
MM-AS	NULL
,	NULL
and	NULL
MM-SV	NULL
)	NULL
were	NULL
examined	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
DR4	NULL
,	NULL
DR5	NULL
,	NULL
DcR1	NULL
,	NULL
and	NULL
DcR2	NULL
receptors	NULL
for	NULL
TRAIL/Apo2L	NULL
.	NULL

The	NULL
Ewing	NULL
sarcoma	NULL
cell	NULL
line	NULL
SK-N-MC	NULL
and	NULL
the	NULL
DHL-4	NULL
and	NULL
DHL-10	NULL
cells	NULL
served	NULL
as	NULL
positive	NULL
controls	NULL
for	NULL
TRAIL/ApoZL	NULL
receptor	NULL
expression	NULL
,	NULL
as	NULL
previously	NULL
documented	NULL
.	NULL
``	NULL

Immunoblotting	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
,	NULL
``	NULL
and	NULL
equal	NULL
protein	NULL
loading	NULL
was	NULL
confirmed	NULL
by	NULL
tubulin	NULL
detection	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
Determination	NULL
of	NULL
TRAIL	NULL
receptor	NULL
status	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
The	NULL
MM	NULL
cells	NULL
were	NULL
characterized	NULL
for	NULL
their	NULL
surface	NULL
expression	NULL
of	NULL
TRAIL	NULL
receptors	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

HeLa	NULL
cells	NULL
served	NULL
as	NULL
positive	NULL
control	NULL
for	NULL
DR4/DR5	NULL
expression	NULL
and	NULL
as	NULL
negative	NULL
controls	NULL
for	NULL
DcR1	NULL
and	NULL
DcR2	NULL
expression	NULL
.	NULL

SK-N-MC	NULL
and	NULL
CHP100S	NULL
Ewing	NULL
sarcoma	NULL
cells	NULL
served	NULL
as	NULL
negative	NULL
controls	NULL
for	NULL
surface	NULL
expression	NULL
of	NULL
DR4	NULL
and	NULL
DR5	NULL
,	NULL
respectively	NULL
.	NULL

DHL-10	NULL
cells	NULL
served	NULL
as	NULL
positive	NULL
control	NULL
for	NULL
DcR1	NULL
and	NULL
DcR2	NULL
expression	NULL
.	NULL

Staining	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

''	NULL
``	NULL
Briefly	NULL
,	NULL
for	NULL
each	NULL
cell	NULL
line	NULL
,	NULL
108	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
appropriate	NULL
anti-TRAIL	NULL
receptor	NULL
antibody	NULL
or	NULL
a	NULL
respective	NULL
control	NULL
(	NULL
5.0	NULL
wg	NULL
)	NULL
for	NULL
45	NULL
minutes	NULL
.	NULL

Specifically	NULL
,	NULL
DR4	NULL
and	NULL
DR5	NULL
expression	NULL
was	NULL
assessed	NULL
with	NULL
anti-DR4	NULL
and	NULL
anti-DR5	NULL
mAbs	NULL
(	NULL
mouse	NULL
IgG1	NULL
and	NULL
IgG2b	NULL
as	NULL
respective	NULL
controls	NULL
)	NULL
and	NULL
confirmed	NULL
with	NULL
goat	NULL
antihuman	NULL
DR4	NULL
and	NULL
DR5	NULL
polyclonal	NULL
antibodies	NULL
,	NULL
using	NULL
goat	NULL
IgG	NULL
for	NULL
control	NULL
staining	NULL
.	NULL

DcR1	NULL
and	NULL
DcR2	NULL
expression	NULL
was	NULL
assessed	NULL
with	NULL
mouse	NULL
anti-DcR1	NULL
and	NULL
DcR2	NULL
mAbs	NULL
and	NULL
goat	NULL
anti-DcR1	NULL
(	NULL
or	NULL
rabbit	NULL
anti-DcR1	NULL
)	NULL
and	NULL
goat	NULL
anti-DcR2	NULL
polyclonal	NULL
antibodies	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
45	NULL
minutes	NULL
with	NULL
2.0	NULL
ug	NULL
goat	NULL
antimouse	NULL
IgG	NULL
FITC-conjugated	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
;	NULL
fragment	NULL
for	NULL
anti-DR4	NULL
and	NULL
anti-DR5	NULL
mAb	NULL
phenotypic	NULL
analyses	NULL
or	NULL
with	NULL
a	NULL
donkey	NULL
antigoat	NULL
IgG	NULL
FITC-conjugated	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
;	NULL
fragment	NULL
for	NULL
the	NULL
DcR1	NULL
,	NULL
DcR2	NULL
,	NULL
DR4	NULL
,	NULL
and	NULL
DRS	NULL
analyses	NULL
with	NULL
the	NULL
goat	NULL
polyclonal	NULL
antibodies	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
,	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
formaldehyde	NULL
PBS	NULL
,	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
EPICS-XL-MCL	NULL
flow	NULL
cytom-eter	NULL
(	NULL
Coulter	NULL
)	NULL
.	NULL

Survival	NULL
,	NULL
death	NULL
,	NULL
and	NULL
apoptosis	NULL
assays	NULL
The	NULL
effect	NULL
of	NULL
TRAIL/Apo2L	NULL
on	NULL
the	NULL
survival	NULL
of	NULL
MM	NULL
cells	NULL
was	NULL
examined	NULL
by	NULL
cell	NULL
cycle	NULL
analyses	NULL
,	NULL
using	NULL
propidium	NULL
iodine	NULL
(	NULL
PI	NULL
)	NULL
staining	NULL
to	NULL
detect	NULL
cells	NULL
in	NULL
sub-G	NULL
,	NULL
gate	NULL
,	NULL
as	NULL
previously	NULL
reported	NULL
``	NULL
and	NULL
3-	NULL
(	NULL
4,5-dimethylthiazol-2-y1	NULL
)	NULL
-2,5-diphenyltetrazolium	NULL
bromide	NULL
(	NULL
MTT	NULL
)	NULL
colorimetric	NULL
assays	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

'*	NULL
Induction	NULL
of	NULL
apoptosis	NULL
was	NULL
confirmed	NULL
and	NULL
quantitatively	NULL
assessed	NULL
by	NULL
annexin	NULL
V/PI	NULL
staining	NULL
and	NULL
Apo2.7	NULL
staining	NULL
.	NULL

PI	NULL
staining	NULL
.	NULL

For	NULL
cell	NULL
cycle	NULL
analysis	NULL
,	NULL
1	NULL
X	NULL
10°	NULL
MM	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
0.001	NULL
to	NULL
1000	NULL
ng/mL	NULL
LZ-TRAIL	NULL
for	NULL
24	NULL
to	NULL
48	NULL
hours	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
,	NULL
permeabilized	NULL
with	NULL
70	NULL
%	NULL
ethanol	NULL
in	NULL
PBS	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
4°C	NULL
,	NULL
incubated	NULL
with	NULL
0.5	NULL
mL	NULL
of	NULL
a	NULL
50-jug/mL	NULL
PI	NULL
solution	NULL
containing	NULL
20	NULL
U/mL	NULL
RNaseA	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
for	NULL
30	NULL
minutes	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

MTT	NULL
colorimetric	NULL
assay	NULL
.	NULL

Cells	NULL
were	NULL
plated	NULL
in	NULL
48-well	NULL
plates	NULL
to	NULL
70	NULL
%	NULL
to	NULL
80	NULL
%	NULL
confluence	NULL
and	NULL
then	NULL
incubated	NULL
for	NULL
18	NULL
hours	NULL
at	NULL
37°C	NULL
with	NULL
LZ-TRAIL	NULL
(	NULL
10-1000	NULL
ng/mL	NULL
)	NULL
in	NULL
2.5	NULL
%	NULL
or	NULL
10	NULL
%	NULL
bovine	NULL
serum-supplemented	NULL
RPMI	NULL
medium	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
MM	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
doxorubicin	NULL
(	NULL
250	NULL
or	NULL
500	NULL
ng/mL	NULL
for	NULL
4	NULL
hours	NULL
)	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
inhibitory	NULL
peptide	NULL
SN50	NULL
(	NULL
or	NULL
its	NULL
mutant	NULL
control	NULL
peptide	NULL
SNSOM	NULL
)	NULL
at	NULL
30	NULL
ng/mL	NULL
for	NULL
3	NULL
hours	NULL
,	NULL
or	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
PS341	NULL
(	NULL
0.1	NULL
M	NULL
for	NULL
4	NULL
hours	NULL
)	NULL
prior	NULL
to	NULL
exposure	NULL
to	NULL
TRAIL	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
repeated	NULL
at	NULL
least	NULL
twice	NULL
,	NULL
and	NULL
each	NULL
experimental	NULL
condition	NULL
was	NULL
repeated	NULL
at	NULL
least	NULL
in	NULL
quadruplicate	NULL
wells	NULL
in	NULL
each	NULL
experi-ment	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
each	NULL
treatment	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
mg/mL	NULL
MTT	NULL
in	NULL
fresh	NULL
media	NULL
for	NULL
4	NULL
hours	NULL
at	NULL
37°C	NULL
.	NULL

A	NULL
mixture	NULL
of	NULL
isopropanol	NULL
and	NULL
1	NULL
N	NULL
HCI	NULL
(	NULL
24:1	NULL
,	NULL
v/v	NULL
)	NULL
was	NULL
added	NULL
under	NULL
vigorous	NULL
pipetting	NULL
to	NULL
dissolve	NULL
the	NULL
formazan	NULL
crystals	NULL
.	NULL

Dye	NULL
absorbance	NULL
(	NULL
A	NULL
)	NULL
in	NULL
viable	NULL
cells	NULL
was	NULL
measured	NULL
at	NULL
570	NULL
nm	NULL
,	NULL
with	NULL
630	NULL
nm	NULL
as	NULL
a	NULL
reference	NULL
wavelength	NULL
.	NULL

Annexin	NULL
V/PI	NULL
staining	NULL
.	NULL

Detection	NULL
of	NULL
early	NULL
apoptotic	NULL
cells	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
annexin	NULL
V-PI	NULL
detection	NULL
kit	NULL
(	NULL
Immunotech/Beckman	NULL
Coulter	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
10°	NULL
MM	NULL
cells	NULL
were	NULL
exposed	NULL
for	NULL
4	NULL
hours	NULL
to	NULL
TRAIL	NULL
or	NULL
media	NULL
,	NULL
washed	NULL
with	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
(	NULL
DMEM	NULL
)	NULL
,	NULL
incubated	NULL
in	NULL
the	NULL
dark	NULL
at	NULL
4°C	NULL
with	NULL
annexin	NULL
V-FITC	NULL
and	NULL
PI	NULL
for	NULL
15	NULL
minutes	NULL
,	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
dual-color	NULL
flow	NULL
cytometry	NULL
.	NULL

Cells	NULL
that	NULL
were	NULL
annexin	NULL
V-FITC*	NULL
(	NULL
with	NULL
translocation	NULL
of	NULL
phosphatidylserine	NULL
from	NULL
the	NULL
inner	NULL
to	NULL
the	NULL
outer	NULL
leaflet	NULL
of	NULL
the	NULL
plasma	NULL
membrane	NULL
)	NULL
and	NULL
PI~	NULL
(	NULL
with	NULL
intact	NULL
cellular	NULL
membrane	NULL
)	NULL
were	NULL
considered	NULL
as	NULL
early	NULL
apoptotic	NULL
cells	NULL
.	NULL

Apo2.7	NULL
staining	NULL
.	NULL

Quantification	NULL
of	NULL
apoptosis	NULL
induction	NULL
was	NULL
also	NULL
performed	NULL
by	NULL
Apo2.7	NULL
immunostaining	NULL
,	NULL
which	NULL
specifically	NULL
detects	NULL
the	NULL
38-kd	NULL
mitochondrial	NULL
membrane	NULL
antigen	NULL
7A6	NULL
that	NULL
is	NULL
exposed	NULL
on	NULL
the	NULL
mitochondrial	NULL
membrane	NULL
of	NULL
apoptotic	NULL
cells	NULL
only	NULL
and	NULL
can	NULL
be	NULL
used	NULL
as	NULL
a	NULL
late	NULL
apoptotic	NULL
marker	NULL
in	NULL
nonpermeabilized	NULL
cells	NULL
.	NULL

``	NULL
>	NULL
>	NULL
*	NULL
MM	NULL
cells	NULL
cultured	NULL
for	NULL
18	NULL
hours	NULL
with	NULL
TRAIL	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
or	NULL
media	NULL
were	NULL
labeled	NULL
with	NULL
the	NULL
Apo2.7-PE	NULL
conjugated	NULL
mAb	NULL
or	NULL
mouse	NULL
IgG1	NULL
isotype	NULL
control	NULL
,	NULL
and	NULL
subsequently	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Effect	NULL
of	NULL
IL-6	NULL
on	NULL
TRAIL-induced	NULL
apoptosis	NULL
The	NULL
MM-18	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
rescued	NULL
by	NULL
IL-6	NULL
from	NULL
Dex-induced	NULL
apopto-sis	NULL
,	NULL
``	NULL
along	NULL
with	NULL
$	NULL
S6B45	NULL
and	NULL
RPMI-8226/S	NULL
cells	NULL
,	NULL
were	NULL
incubated	NULL
for	NULL
24	NULL
hours	NULL
with	NULL
TRAIL	NULL
(	NULL
in	NULL
concentrations	NULL
up	NULL
to	NULL
1000	NULL
ng/mL	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
.	NULL

Survival	NULL
of	NULL
MM	NULL
cells	NULL
was	NULL
then	NULL
assessed	NULL
by	NULL
MTT	NULL
assay	NULL
and	NULL
PI	NULL
.	NULL

Sensitization	NULL
to	NULL
TRAIL-induced	NULL
apoptosis	NULL
by	NULL
Dox	NULL
,	NULL
NF-B	NULL
inhibitor	NULL
,	NULL
and	NULL
proteasome	NULL
inhibitor	NULL
The	NULL
MM-18	NULL
and	NULL
Dex-resistant	NULL
MM-1R	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
RPMI-8226/S	NULL
and	NULL
the	NULL
Dox-resistant	NULL
RPMI-8226/Dox40	NULL
cells	NULL
,	NULL
were	NULL
preincubated	NULL
with	NULL
Dox	NULL
(	NULL
250	NULL
or	NULL
500	NULL
ng/mL	NULL
.	NULL
)	NULL

for	NULL
4	NULL
hours	NULL
.	NULL

MM-18	NULL
,	NULL
RPMI-8226/8	NULL
,	NULL
ARH-77	NULL
,	NULL
and	NULL
IM-9	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
4	NULL
hours	NULL
with	NULL
the	NULL
NF-B	NULL
inhibitory	NULL
peptide	NULL
SN-50	NULL
or	NULL
its	NULL
mutant	NULL
control	NULL
peptide	NULL
SN-50M	NULL
.	NULL

MM-18	NULL
cells	NULL
were	NULL
also	NULL
preincubated	NULL
with	NULL
0.1	NULL
wM	NULL
of	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
PS-341	NULL
for	NULL
4	NULL
hours	NULL
.	NULL

Following	NULL
each	NULL
of	NULL
these	NULL
pretreatments	NULL
,	NULL
TRAIL	NULL
(	NULL
50	NULL
or	NULL
100	NULL
ng/mL	NULL
)	NULL
was	NULL
added	NULL
for	NULL
18	NULL
hours	NULL
,	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
MTT	NULL
assay	NULL
.	NULL

Effect	NULL
of	NULL
TRAIL	NULL
on	NULL
healthy	NULL
donor	NULL
B	NULL
cells	NULL
Peripheral	NULL
blood	NULL
B	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
5	NULL
healthy	NULL
donors	NULL
by	NULL
Ficoll-Hypaque	NULL
(	NULL
Pharmacia	NULL
)	NULL
density	NULL
centrifugation	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
,	NULL
depletion	NULL
of	NULL
monocytes	NULL
by	NULL
overnight	NULL
adhesion	NULL
on	NULL
plastic	NULL
,	NULL
and	NULL
enrichment	NULL
for	NULL
B	NULL
cells	NULL
either	NULL
by	NULL
removal	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
sheep	NULL
red	NULL
blood	NULL
cell	NULL
rosetting	NULL
or	NULL
by	NULL
positive	NULL
selection	NULL
for	NULL
CD19+*	NULL
cells	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
.	NULL

B	NULL
cells	NULL
(	NULL
>	NULL
85	NULL
%	NULL
CD19+*	NULL
)	NULL
or	NULL
unpurified	NULL
PBMCs	NULL
or	NULL
BMMCs	NULL
were	NULL
exposed	NULL
to	NULL
TRAIL	NULL
(	NULL
10-1000	NULL
ng/mL	NULL
)	NULL
for	NULL
18	NULL
to	NULL
24	NULL
hours	NULL
.	NULL

Normal	NULL
PBMCs	NULL
or	NULL
B	NULL
cells	NULL
were	NULL
also	NULL
pretreated	NULL
with	NULL
Dox	NULL
,	NULL
PS-341	NULL
,	NULL
or	NULL
SN50	NULL
before	NULL
exposure	NULL
to	NULL
TRAIL	NULL
(	NULL
50-100	NULL
ng/mL	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
administration	NULL
of	NULL
TRAIL	NULL
to	NULL
nu/xid/bg	NULL
mice	NULL
xenografted	NULL
with	NULL
human	NULL
plasmacytomas	NULL
Six-	NULL
to	NULL
8-week-old	NULL
male	NULL
nu/xid/bg	NULL
mice	NULL
obtained	NULL
from	NULL
Jackson	NULL
Laboratories	NULL
(	NULL
Wilmington	NULL
,	NULL
DE	NULL
)	NULL
were	NULL
cared	NULL
for	NULL
in	NULL
the	NULL
animal	NULL
research	NULL
facility	NULL
of	NULL
the	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
in	NULL
accordance	NULL
with	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
guidelines	NULL
and	NULL
those	NULL
of	NULL
the	NULL
Animal	NULL
Care	NULL
and	NULL
Use	NULL
Committee	NULL
at	NULL
our	NULL
institution	NULL
.	NULL

Mice	NULL
were	NULL
engrafted	NULL
with	NULL
10	NULL
``	NULL
S6B45	NULL
human	NULL
MM	NULL
cells	NULL
by	NULL
subcutaneous	NULL
injection	NULL
in	NULL
the	NULL
right	NULL
flank	NULL
.	NULL

On	NULL
formation	NULL
of	NULL
a	NULL
palpable	NULL
tumor	NULL
,	NULL
mice	NULL
were	NULL
randomly	NULL
placed	NULL
into	NULL
2	NULL
cohorts	NULL
of	NULL
8	NULL
mice	NULL
and	NULL
received	NULL
either	NULL
PBS	NULL
or	NULL
recombinant	NULL
human	NULL
TRAIL	NULL
at	NULL
500	NULL
jpg	NULL
daily	NULL
by	NULL
intraperitoneal	NULL
administration	NULL
for	NULL
14	NULL
consecutive	NULL
days	NULL
.	NULL

Tumor	NULL
volumes	NULL
and	NULL
weights	NULL
for	NULL
the	NULL
treated	NULL
mice	NULL
were	NULL
obtained	NULL
every	NULL
other	NULL
day	NULL
.	NULL

Statistical	NULL
analysis	NULL
The	NULL
potential	NULL
correlation	NULL
of	NULL
TRAIL	NULL
receptor	NULL
status	NULL
profile	NULL
with	NULL
the	NULL
sensitivity	NULL
or	NULL
resistance	NULL
of	NULL
each	NULL
cell	NULL
line	NULL
to	NULL
TRAIL	NULL
was	NULL
evaluated	NULL
with	NULL
the	NULL
use	NULL
of	NULL
the	NULL
McNemar	NULL
paired	NULL
y	NULL
test	NULL
.	NULL

The	NULL
tumor	NULL
volumes	NULL
of	NULL
human	NULL
plasmacytoma	NULL
xenografts	NULL
(	NULL
at	NULL
days	NULL
1	NULL
,	NULL
5	NULL
,	NULL
8	NULL
,	NULL
11	NULL
,	NULL
14	NULL
,	NULL
and	NULL
18	NULL
after	NULL
initiation	NULL
of	NULL
TRAIL	NULL
administration	NULL
)	NULL
were	NULL
compared	NULL
with	NULL
the	NULL
PBS-treated	NULL
controls	NULL
by	NULL
the	NULL
Mann-Whitney	NULL
U	NULL
test	NULL
.	NULL

One-way	NULL
analysis	NULL
of	NULL
variance	NULL
and	NULL
the	NULL
Duncan	NULL
post	NULL
hoc	NULL
test	NULL
was	NULL
performed	NULL
to	NULL
compare	NULL
,	NULL
within	NULL
the	NULL
TRAIL-treated	NULL
cohort	NULL
(	NULL
or	NULL
the	NULL
control	NULL
group	NULL
)	NULL
,	NULL
the	NULL
tumor	NULL
volumes	NULL
at	NULL
different	NULL
time	NULL
points	NULL
of	NULL
the	NULL
study	NULL
.	NULL

Interactions	NULL
between	NULL
TRAIL	NULL
and	NULL
Dox	NULL
,	NULL
NF-B	NULL
inhibitory	NULL
peptide	NULL
,	NULL
or	NULL
PS-341	NULL
were	NULL
classified	NULL
by	NULL
the	NULL
fractional	NULL
inhibition	NULL
method	NULL
,	NULL
as	NULL
previously	NULL
de-scribed	NULL
,	NULL
``	NULL
``	NULL
and	NULL
also	NULL
examined	NULL
by	NULL
a	NULL
2-way	NULL
analysis	NULL
of	NULL
variance	NULL
,	NULL
followed	NULL
by	NULL
the	NULL
Duncan	NULL
post	NULL
hoc	NULL
test	NULL
.	NULL

A	NULL
P	NULL
value	NULL
less	NULL
than	NULL
.05	NULL
was	NULL
considered	NULL
statistically	NULL
significant	NULL
.	NULL

TRAIL/Apo2L-INDUCED	NULL
APOPTOSIS	NULL
OF	NULL
MULTIPLE	NULL
MYELOMA	NULL
CELLS	NULL
_	NULL
797	NULL
Results	NULL
TRAIL/Apo2L	NULL
induces	NULL
apoptosis	NULL
of	NULL
MM	NULL
cell	NULL
lines	NULL
and	NULL
MM	NULL
patient	NULL
cells	NULL
We	NULL
first	NULL
determined	NULL
the	NULL
effect	NULL
of	NULL
TRAIL/Apo2L	NULL
on	NULL
chemotherapy-sensitive	NULL
and	NULL
chemotherapy-resistant	NULL
MM	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
patient	NULL
MM	NULL
cells	NULL
.	NULL

In	NULL
10	NULL
of	NULL
16	NULL
lines	NULL
tested	NULL
(	NULL
ARP-1	NULL
,	NULL
MM-18	NULL
,	NULL
MM-1R	NULL
,	NULL
RPMI-8226/S	NULL
,	NULL
Dox6	NULL
,	NULL
Dox40	NULL
,	NULL
LR5	NULL
,	NULL
MR20	NULL
,	NULL
U266	NULL
,	NULL
and	NULL
S6B45	NULL
)	NULL
,	NULL
TRAIL/Apo2L	NULL
induced	NULL
significant	NULL
reductions	NULL
in	NULL
cell	NULL
survival	NULL
(	NULL
with	NULL
median	NULL
effective	NULL
dose	NULL
values	NULL
of	NULL
<	NULL
300	NULL
ng/mL	NULL
)	NULL
,	NULL
assessed	NULL
by	NULL
the	NULL
MTT	NULL
assay	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

Five	NULL
MM	NULL
lines	NULL
,	NULL
ARH-77	NULL
,	NULL
HS	NULL
Sultan	NULL
,	NULL
IM-9	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
,	NULL
MM-AS	NULL
,	NULL
and	NULL
MM-SV	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
had	NULL
more	NULL
than	NULL
70	NULL
%	NULL
survival	NULL
after	NULL
exposure	NULL
to	NULL
doses	NULL
of	NULL
TRAIL/Apo2L	NULL
as	NULL
high	NULL
as	NULL
1000	NULL
ng/mL	NULL
and	NULL
were	NULL
considered	NULL
TRAIL	NULL
resistant	NULL
.	NULL

The	NULL
OCI-My5	NULL
cells	NULL
had	NULL
an	NULL
intermediate	NULL
pattern	NULL
of	NULL
120	NULL
100	NULL
so	NULL
a	NULL
Rs	NULL
Z	NULL
60	NULL
5	NULL
-C-	NULL
MM-18	NULL
C	NULL
-O-	NULL
MM-IR	NULL
&	NULL
40	NULL
G	NULL
a	NULL
--	NULL
@	NULL
®-	NULL
RPMI-8226/Dox6	NULL
-Q-	NULL
RPMI-8226/Dox40	NULL
3	NULL
4	NULL
20	NULL
|	NULL
-Q-	NULL
RPMLS226/LRS	NULL
--	NULL
RPMI-8226/MR20	NULL
--	NULL
ARP-1	NULL
9	NULL
4	NULL
-a-	NULL
OCl-MyS	NULL
--	NULL
t	NULL
0	NULL
10	NULL
30	NULL
100	NULL
300	NULL
1000	NULL
TRAIL	NULL
(	NULL
ng/mL	NULL
)	NULL
120	NULL
110	NULL
100	NULL
~	NULL
90	NULL
ee	NULL
a	NULL
&	NULL
0	NULL
107	NULL
_	NULL
o	NULL
60	NULL
w	NULL
s=	NULL
-	NULL
&	NULL
-	NULL
HS	NULL
Sultan	NULL
y	NULL
0	NULL
-	NULL
&	NULL
-	NULL
IM-9	NULL
40	NULL
-	NULL
-	NULL
@	NULL
-	NULL
ARH-77	NULL
30	NULL
-	NULL
-1-	NULL
Normal	NULL
B	NULL
cells	NULL
20	NULL
10	NULL
0	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
30	NULL
100	NULL
300	NULL
1000	NULL
TRAIL	NULL
(	NULL
ng/mL	NULL
)	NULL
Figure	NULL
1	NULL
.	NULL

MTT	NULL
assay	NULL
of	NULL
MM	NULL
cells	NULL
and	NULL
healthy	NULL
donor	NULL
B	NULL
cells	NULL
cultured	NULL
with	NULL
human	NULL
recombinant	NULL
TRAIL	NULL
.	NULL

Dose-response	NULL
survival	NULL
curves	NULL
based	NULL
on	NULL
MTT	NULL
colorimetric	NULL
assay	NULL
were	NULL
generated	NULL
for	NULL
MM	NULL
cells	NULL
and	NULL
healthy	NULL
donor	NULL
B	NULL
cells	NULL
cultured	NULL
for	NULL
18	NULL
hours	NULL
with	NULL
TRAIL	NULL
(	NULL
10-1000	NULL
ng/mL	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Dose-response	NULL
survival	NULL
curves	NULL
are	NULL
shown	NULL
for	NULL
TRAIL-sensitive	NULL
MM	NULL
cell	NULL
lines	NULL
ARP-1	NULL
;	NULL
Dex-sensitive	NULL
MM-1S	NULL
and	NULL
Dex-resistant	NULL
MM-1	NULL
R	NULL
;	NULL
RPMI-8226/S	NULL
and	NULL
its	NULL
cytotoxic	NULL
drug-resistant	NULL
sublines	NULL
Dox6	NULL
,	NULL
Dox40	NULL
,	NULL
MR20	NULL
,	NULL
and	NULL
LRS	NULL
;	NULL
as	NULL
well	NULL
as	NULL
the	NULL
response	NULL
of	NULL
OCI-My5	NULL
cells	NULL
,	NULL
which	NULL
have	NULL
intermediate	NULL
TRAIL	NULL
sensitivity	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Dose-response	NULL
survival	NULL
curves	NULL
are	NULL
shown	NULL
for	NULL
TRAIL-resistant	NULL
ARH-77	NULL
,	NULL
HS	NULL
Sultan	NULL
,	NULL
and	NULL
IM-9	NULL
MM	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
healthy	NULL
donor	NULL
peripheral	NULL
blood	NULL
B	NULL
cells	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

798	NULL
_	NULL
MITSIADES	NULL
etal	NULL
TRAIL-induced	NULL
cell	NULL
death	NULL
,	NULL
with	NULL
about	NULL
50	NULL
%	NULL
survival	NULL
at	NULL
a	NULL
TRAIL	NULL
dose	NULL
of	NULL
1000	NULL
ng/mL	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
,	NULL
indicating	NULL
moderate	NULL
TRAIL	NULL
sensitivity	NULL
.	NULL

The	NULL
TRAIL	NULL
sensitivity	NULL
or	NULL
resistance	NULL
of	NULL
MM	NULL
cells	NULL
was	NULL
confirmed	NULL
by	NULL
annexin	NULL
V-FITC/PI	NULL
staining	NULL
(	NULL
for	NULL
detection	NULL
of	NULL
early	NULL
apoptotic	NULL
annexin	NULL
V*	NULL
PI~	NULL
cells	NULL
)	NULL
(	NULL
Figure	NULL
2A-C	NULL
)	NULL
,	NULL
cell	NULL
cycle	NULL
analysis	NULL
following	NULL
PI	NULL
staining	NULL
(	NULL
Figure	NULL
2D	NULL
,	NULL
E	NULL
)	NULL
,	NULL
and	NULL
staining	NULL
with	NULL
the	NULL
Apo2.7	NULL
mAb	NULL
for	NULL
detection	NULL
of	NULL
late	NULL
apoptotic	NULL
cells	NULL
(	NULL
Figure	NULL
2F	NULL
)	NULL
.	NULL

We	NULL
also	NULL
evaluated	NULL
the	NULL
effect	NULL
of	NULL
TRAIL/ApoZL	NULL
on	NULL
freshly	NULL
isolated	NULL
MM	NULL
cells	NULL
from	NULL
5	NULL
patients	NULL
.	NULL

MM	NULL
(	NULL
CD38*/CD45SRA~	NULL
)	NULL
cells	NULL
treated	NULL
with	NULL
TRAIL	NULL
(	NULL
>	NULL
100	NULL
ng/mL	NULL
)	NULL
had	NULL
significant	NULL
increases	NULL
,	NULL
compared	NULL
to	NULL
control	NULL
,	NULL
in	NULL
the	NULL
fraction	NULL
of	NULL
sub-G	NULL
;	NULL
cells	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
normal	NULL
B	NULL
cells	NULL
were	NULL
resistant	NULL
to	NULL
TRAIL	NULL
concentrations	NULL
as	NULL
high	NULL
as	NULL
1000	NULL
ng/mL	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

Apoptosis	NULL
of	NULL
MM	NULL
patient	NULL
BMMCs	NULL
cultured	NULL
for	NULL
18	NULL
hours	NULL
with	NULL
TRAIL	NULL
(	NULL
1000	NULL
and	NULL
300	NULL
ng/mL	NULL
)	NULL
was	NULL
also	NULL
assessed	NULL
by	NULL
dual-color	NULL
flow	NULL
cytometry	NULL
for	NULL
CD38-FITC/	NULL
Apo2.7-PE	NULL
(	NULL
to	NULL
detect	NULL
late	NULL
apoptotic	NULL
Apo2.7+/CD38*	NULL
cells	NULL
)	NULL
.	NULL

Control	NULL
cultures	NULL
stained	NULL
with	NULL
CD38-FITC	NULL
and	NULL
Apo2.7-PE	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
indicated	NULL
very	NULL
few	NULL
late	NULL
apoptotic	NULL
cells	NULL
in	NULL
either	NULL
CD38*	NULL
or	NULL
CD38~	NULL
BMMCs	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
treatment	NULL
with	NULL
TRAIL	NULL
at	NULL
1000	NULL
ng/mL	NULL
(	NULL
Figure	NULL
A	NULL
D	NULL
UZ	NULL
MM-18	NULL
control	NULL
02	NULL
%	NULL
a	NULL
5	NULL
S6B45	NULL
3	NULL
80.3	NULL
%	NULL
28	NULL
f	NULL
EU	NULL
1023	NULL
10	NULL
10	NULL
'	NULL
10°	NULL
10°	NULL
ot	NULL
i	NULL
97.5	NULL
%	NULL
Annexin	NULL
V-FIIC	NULL
22	NULL
%	NULL
B	NULL
E	NULL
°°	NULL
_	NULL
MM-18	NULL
TRAIL	NULL
100	NULL
ngiml	NULL
_'**	NULL
U266	NULL
&	NULL
|83.1	NULL
%	NULL
#	NULL
£	NULL
a2	NULL
&	NULL
©	NULL
C	NULL
‘	NULL
0	NULL
1023	NULL
3	NULL
P	NULL
``	NULL
Ho	NULL
``	NULL
10°	NULL
10	NULL
``	NULL
10+	NULL
10°	NULL
'	NULL
&	NULL
%	NULL
&	NULL
=	NULL
Annexin	NULL
V-HITC	NULL
20.2	NULL
%	NULL
°C	NULL
-	NULL
MM-1S	NULL
TRAIL	NULL
1000	NULL
ngimL	NULL
***	NULL
MM-18	NULL
TRAIL	NULL
1000	NULL
ng/mL	NULL
vs	NULL
control	NULL
.	NULL

3	NULL
(	NULL
27.0	NULL
%	NULL
)	NULL
M	NULL
P	NULL
-__-M	NULL
£	NULL
a	NULL
5	NULL
a	NULL
2	NULL
C	NULL
``	NULL
10°	NULL
To	NULL
'	NULL
To	NULL
:	NULL
To	NULL
at	NULL
10°	NULL
10°	NULL
9°	NULL
tof	NULL
70	NULL
%	NULL
Annexin	NULL
¥-FIrC	NULL
825	NULL
%	NULL
Figure	NULL
2	NULL
.	NULL

Annexin/Pl	NULL
staining	NULL
,	NULL
cell	NULL
cycle	NULL
analysis	NULL
,	NULL
and	NULL
Apo2.7	NULL
staining	NULL
of	NULL
MM	NULL
cells	NULL
cultured	NULL
with	NULL
human	NULL
recombinant	NULL
TRAIL	NULL
.	NULL

(	NULL
A-C	NULL
)	NULL
MM	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
TRAIL	NULL
(	NULL
100	NULL
and	NULL
1000	NULL
ng/mL	NULL
)	NULL
for	NULL
4	NULL
hours	NULL
.	NULL

Representative	NULL
dual	NULL
staining	NULL
for	NULL
annexin-FITC/	NULL
(	NULL
P	NULL
!	NULL
)	NULL

indicates	NULL
significant	NULL
induction	NULL
of	NULL
apoptotic	NULL
cell	NULL
death	NULL
(	NULL
annexin*	NULL
PI~	NULL
status	NULL
)	NULL
of	NULL
MM-1S	NULL
MM	NULL
cells	NULL
.	NULL

(	NULL
D	NULL
,	NULL
E	NULL
)	NULL
Representative	NULL
PI	NULL
staining	NULL
of	NULL
MM	NULL
cells	NULL
following	NULL
24-hour	NULL
culture	NULL
with	NULL
TRAIL	NULL
(	NULL
1000	NULL
ng/mL	NULL
)	NULL
or	NULL
control	NULL
cultures	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
sub-G	NULL
;	NULL
region	NULL
(	NULL
indicated	NULL
in	NULL
each	NULL
graph	NULL
)	NULL
documents	NULL
the	NULL
significant	NULL
TRAIL-induced	NULL
cell	NULL
death	NULL
of	NULL
S6B45	NULL
and	NULL
U266	NULL
cells	NULL
.	NULL

(	NULL
F	NULL
)	NULL
Detection	NULL
of	NULL
late	NULL
apoptosis	NULL
by	NULL
staining	NULL
with	NULL
the	NULL
Apo2.7	NULL
mAb	NULL
.	NULL

The	NULL
curves	NULL
corresponding	NULL
to	NULL
the	NULL
MsigG1-PE	NULL
control	NULL
for	NULL
the	NULL
TRAIL-treated	NULL
(	NULL
standard	NULL
line	NULL
)	NULL
and	NULL
control	NULL
(	NULL
dotted	NULL
line	NULL
)	NULL
cultures	NULL
of	NULL
MM-1S	NULL
cells	NULL
are	NULL
superimposable	NULL
with	NULL
the	NULL
(	NULL
shaded	NULL
)	NULL
curve	NULL
for	NULL
Apo2.7	NULL
staining	NULL
in	NULL
the	NULL
control	NULL
culture	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
TRAIL-treated	NULL
MM	NULL
cells	NULL
have	NULL
strong	NULL
staining	NULL
for	NULL
the	NULL
Apo2.7	NULL
(	NULL
unshaded	NULL
curve	NULL
)	NULL
,	NULL
which	NULL
is	NULL
consistent	NULL
with	NULL
extensive	NULL
induction	NULL
of	NULL
cell	NULL
death	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
R	NULL
2	NULL
TRAIL	NULL
10	NULL
ng/mL	NULL
a	NULL
o	NULL
TRAIL	NULL
50	NULL
ng/mL	NULL
9	NULL
2	NULL
E	NULL
TRAIL	NULL
100	NULL
ng/mL	NULL
Z	NULL
TRAIL	NULL
500	NULL
ng/mL	NULL
Control	NULL
subG	NULL
!	NULL

PI	NULL
**	NULL
MM	NULL
pt	NULL
control	NULL
2	NULL
%	NULL
``	NULL
5	NULL
``	NULL
MM	NULL
pt	NULL
TRAIL	NULL
1000	NULL
ng/mL	NULL
``	NULL
**	NULL
I	NULL
i	NULL
®	NULL
E.	NULL
f	NULL
B	NULL
A	NULL
a	NULL
10°	NULL
10°	NULL
10°	NULL
ot	NULL
10°	NULL
ity	NULL
10°	NULL
10°	NULL
ot	NULL
757	NULL
%	NULL
Apor7-98	NULL
02	NULL
%	NULL
78.3	NULL
%	NULL
Apor.-8	NULL
12	NULL
%	NULL
Figure	NULL
3	NULL
.	NULL

TRAIL	NULL
induces	NULL
cell	NULL
death	NULL
of	NULL
freshly	NULL
isolated	NULL
MM	NULL
patient	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Representative	NULL
3-dimensional	NULL
cell	NULL
cycle	NULL
profile	NULL
analysis	NULL
,	NULL
by	NULL
PI	NULL
staining	NULL
,	NULL
of	NULL
freshly	NULL
isolated	NULL
CD38+/CD45RA~	NULL
malignant	NULL
cells	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
plasma	NULL
cell	NULL
leukemia	NULL
.	NULL

(	NULL
The	NULL
longitudinal	NULL
axis	NULL
corresponds	NULL
to	NULL
intensity	NULL
of	NULL
PI	NULL
staining	NULL
and	NULL
the	NULL
vertical	NULL
axis	NULL
to	NULL
number	NULL
of	NULL
events	NULL
.	NULL
)	NULL

A	NULL
24-hour	NULL
incubation	NULL
with	NULL
TRAIL	NULL
induced	NULL
significant	NULL
cell	NULL
death	NULL
documented	NULL
by	NULL
the	NULL
shift	NULL
of	NULL
cells	NULL
to	NULL
the	NULL
sub-G	NULL
;	NULL
region	NULL
(	NULL
indicated	NULL
by	NULL
the	NULL
dark	NULL
shaded	NULL
portions	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
profiles	NULL
)	NULL
.	NULL

(	NULL
B	NULL
,	NULL
C	NULL
)	NULL
Effect	NULL
of	NULL
TRAIL	NULL
on	NULL
freshly	NULL
isolated	NULL
MM	NULL
patient	NULL
BMMCs	NULL
.	NULL

Dual-color	NULL
flow	NULL
cytometry	NULL
for	NULL
CD38-FITC	NULL
and	NULL
Apo2.7-PE	NULL
indicates	NULL
that	NULL
late	NULL
apoptotic	NULL
(	NULL
Apo2.7-PE*	NULL
)	NULL
cells	NULL
are	NULL
present	NULL
only	NULL
in	NULL
the	NULL
population	NULL
of	NULL
CD38+	NULL
BMMCs	NULL
,	NULL
which	NULL
contains	NULL
MM	NULL
plasma	NULL
cells	NULL
.	NULL

Quadrants	NULL
were	NULL
set	NULL
based	NULL
on	NULL
negative	NULL
controls	NULL
stained	NULL
with	NULL
MsigG1-FITC	NULL
and	NULL
MsigG1-PE	NULL
(	NULL
X-axis	NULL
,	NULL
Apo2.7	NULL
relative	NULL
expression	NULL
;	NULL
Y-axis	NULL
,	NULL
CD38	NULL
relative	NULL
expression	NULL
)	NULL
.	NULL

3C	NULL
)	NULL
or	NULL
300	NULL
ng/mL	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
led	NULL
to	NULL
a	NULL
distinct	NULL
population	NULL
of	NULL
late	NULL
apoptotic	NULL
Apo2.7+*	NULL
cells	NULL
within	NULL
the	NULL
CD38*	NULL
fraction	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
MM	NULL
cells	NULL
;	NULL
approximately	NULL
40	NULL
%	NULL
and	NULL
35	NULL
%	NULL
of	NULL
CD38+	NULL
cells	NULL
were	NULL
also	NULL
Apo2.7+*	NULL
after	NULL
treatment	NULL
with	NULL
TRAIL	NULL
at	NULL
1000	NULL
(	NULL
Figure	NULL
3C	NULL
)	NULL
and	NULL
300	NULL
ng/mL	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Importantly	NULL
,	NULL
in	NULL
none	NULL
of	NULL
TRAIL-treated	NULL
cultures	NULL
did	NULL
we	NULL
detect	NULL
any	NULL
increase	NULL
in	NULL
Apo2.7*	NULL
cells	NULL
among	NULL
the	NULL
CD38~	NULL
(	NULL
non-MM	NULL
BMMC	NULL
)	NULL
population	NULL
(	NULL
<	NULL
2.5	NULL
%	NULL
of	NULL
Apo2.7+*/CD38~	NULL
cells	NULL
in	NULL
either	NULL
TRAIL-treated	NULL
or	NULL
control	NULL
cultures	NULL
)	NULL
.	NULL

Further	NULL
analysis	NULL
by	NULL
staining	NULL
of	NULL
TRAIL-treated	NULL
cells	NULL
with	NULL
anti-CD45RA-FITC	NULL
mAb	NULL
confirmed	NULL
Apo2.7+*	NULL
staining	NULL
of	NULL
only	NULL
CD38*/CD45RA~	NULL
BMMCs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
selective	NULL
killing	NULL
of	NULL
myeloma	NULL
cells	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
notion	NULL
that	NULL
TRAIL	NULL
almost	NULL
exclusively	NULL
targets	NULL
malignant	NULL
plasma	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
normal	NULL
BMMCs	NULL
from	NULL
patients	NULL
with	NULL
MM	NULL
.	NULL

Effect	NULL
of	NULL
TRAIL/Apo2L	NULL
on	NULL
healthy	NULL
donor	NULL
B	NULL
cells	NULL
and	NULL
BMMCs	NULL
We	NULL
next	NULL
investigated	NULL
whether	NULL
the	NULL
proapoptotic	NULL
effect	NULL
of	NULL
TRAIL/	NULL
Apo2L	NULL
is	NULL
selective	NULL
against	NULL
MM	NULL
cells	NULL
or	NULL
whether	NULL
it	NULL
may	NULL
also	NULL
affect	NULL
normal	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Peripheral	NULL
blood	NULL
normal	NULL
B	NULL
cells	NULL
from	NULL
7	NULL
healthy	NULL
donors	NULL
,	NULL
as	NULL
well	NULL
as	NULL
BMMCs	NULL
from	NULL
another	NULL
3	NULL
donors	NULL
,	NULL
were	NULL
incubated	NULL
with	NULL
LZ-TRAIL	NULL
at	NULL
concentrations	NULL
(	NULL
10-1000	NULL
ng/mL	NULL
)	NULL
that	NULL
induce	NULL
MM	NULL
cell	NULL
apoptosis	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
dead/apoptotic	NULL
(	NULL
sub-G	NULL
;	NULL
region	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
profile	NULL
)	NULL
normal	NULL
B	NULL
cells	NULL
after	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
a	NULL
jg	NULL
TRAIL	NULL
10	NULL
ng/mL	NULL
a	NULL
;	NULL
TRAIL	NULL
50	NULL
ng/mL	NULL
g	NULL
TRAIL	NULL
100	NULL
ng/mL	NULL
E	NULL
Z	NULL
TRAIL	NULL
300	NULL
ng/mL	NULL
TRAIL	NULL
1000	NULL
ng/mL	NULL
Control	NULL
suEGl	NULL
P	NULL
I	NULL
205	NULL
%	NULL
Control	NULL
nas	NULL
198	NULL
%	NULL
TRAIL	NULL
1000	NULL
ng/mL	NULL
nex	NULL
coss.rite	NULL
1950	NULL
.	NULL

Br	NULL
15	NULL
>	NULL
B	NULL
ot	NULL
10	NULL
!	NULL

10°	NULL
ot	NULL
10°	NULL
10	NULL
``	NULL
0	NULL
10°	NULL
l	NULL
Apo	NULL
7-95	NULL
05	NULL
%	NULL
Figure	NULL
4	NULL
.	NULL

Effect	NULL
of	NULL
TRAIL	NULL
on	NULL
normal	NULL
PBMCs	NULL
or	NULL
BMMCs	NULL
.	NULL

PBMCs	NULL
and	NULL
BMMCs	NULL
of	NULL
healthy	NULL
donors	NULL
were	NULL
treated	NULL
with	NULL
TRAIL	NULL
(	NULL
at	NULL
concentrations	NULL
up	NULL
to	NULL
1000	NULL
ng/mL	NULL
)	NULL
for	NULL
24	NULL
hours	NULL
.	NULL

A	NULL
dose-response	NULL
analysis	NULL
(	NULL
by	NULL
PI	NULL
staining	NULL
)	NULL
of	NULL
the	NULL
normal	NULL
B	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
indicates	NULL
no	NULL
shift	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
sub-G	NULL
;	NULL
region	NULL
,	NULL
consistent	NULL
with	NULL
lack	NULL
of	NULL
TRAIL-induced	NULL
cell	NULL
death	NULL
at	NULL
concentrations	NULL
up	NULL
to	NULL
1000	NULL
ng/mL	NULL
.	NULL

Panels	NULL
B	NULL
and	NULL
C	NULL
demonstrate	NULL
that	NULL
healthy	NULL
donor	NULL
's	NULL
BMMCs	NULL
are	NULL
resistant	NULL
to	NULL
even	NULL
1000	NULL
ng/mL	NULL
TRAIL	NULL
.	NULL

Dual-color	NULL
flow	NULL
cytometry	NULL
,	NULL
for	NULL
CD38+-FITC	NULL
and	NULL
Apo2.7-PE	NULL
revealed	NULL
that	NULL
apoptotic	NULL
cells	NULL
(	NULL
Apo2.7-PE*	NULL
)	NULL
are	NULL
not	NULL
detected	NULL
in	NULL
either	NULL
the	NULL
CD38+	NULL
or	NULL
CD38~	NULL
populations	NULL
of	NULL
BMMCs	NULL
.	NULL

(	NULL
Quadrants	NULL
were	NULL
set	NULL
based	NULL
on	NULL
negative	NULL
controls	NULL
stained	NULL
with	NULL
MslgG1-FITC	NULL
and	NULL
MslgG1-PE	NULL
.	NULL
)	NULL

1	NULL
10	NULL
``	NULL
rast	NULL
Apor	NULL
.	NULL

ree	NULL
exposure	NULL
to	NULL
TRAIL/Apo2L	NULL
did	NULL
not	NULL
differ	NULL
from	NULL
untreated	NULL
controls	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

MTT	NULL
assays	NULL
of	NULL
normal	NULL
donor	NULL
PBMCs	NULL
revealed	NULL
no	NULL
TRAIL-induced	NULL
reduction	NULL
in	NULL
survival	NULL
,	NULL
whereas	NULL
Apo2.7	NULL
staining	NULL
of	NULL
normal	NULL
donor	NULL
PBMCs	NULL
with	NULL
counterstaining	NULL
for	NULL
CD19	NULL
,	NULL
CD3	NULL
,	NULL
or	NULL
CD14	NULL
revealed	NULL
no	NULL
reduction	NULL
in	NULL
the	NULL
survival	NULL
of	NULL
B	NULL
lymphocytes	NULL
,	NULL
T	NULL
lymphocytes	NULL
,	NULL
and	NULL
monocytes/macrophages	NULL
,	NULL
respectively	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Normal	NULL
donor	NULL
BMMCs	NULL
were	NULL
also	NULL
treated	NULL
with	NULL
TRAIL	NULL
(	NULL
100-1000	NULL
ng/mL	NULL
)	NULL
for	NULL
18	NULL
hours	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
dual-color	NULL
flow	NULL
cytometry	NULL
for	NULL
CD38-FITC/Apo2.7-PE	NULL
(	NULL
to	NULL
detect	NULL
late	NULL
apoptotic	NULL
Apo2.7*	NULL
cells	NULL
)	NULL
.	NULL

TRAIL	NULL
induced	NULL
apoptosis	NULL
of	NULL
neither	NULL
CD38*	NULL
or	NULL
CD38~	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
survival	NULL
of	NULL
normal	NULL
plasma	NULL
cells	NULL
or	NULL
other	NULL
populations	NULL
of	NULL
normal	NULL
BMMCs	NULL
(	NULL
Figure	NULL
4B	NULL
,	NULL
C	NULL
)	NULL
.	NULL

IL-6	NULL
does	NULL
not	NULL
confer	NULL
resistance	NULL
to	NULL
TRAIL-induced	NULL
apoptosis	NULL
Interleukin	NULL
6	NULL
is	NULL
a	NULL
potent	NULL
growth	NULL
and	NULL
survival	NULL
factor	NULL
for	NULL
MM	NULL
cells	NULL
and	NULL
is	NULL
known	NULL
to	NULL
inhibit	NULL
apoptosis	NULL
induced	NULL
by	NULL
Dex	NULL
``	NULL
and	NULL
TRAIL-related	NULL
FasL	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
We	NULL
therefore	NULL
examined	NULL
whether	NULL
IL-6	NULL
blocks	NULL
TRAIL-induced	NULL
apoptosis	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

MM-1S	NULL
,	NULL
S	NULL
$	NULL
6B45	NULL
,	NULL
and	NULL
RPMI-8226/8	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
TRAIL	NULL
(	NULL
0.001-1000	NULL
ng/mL	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-6	NULL
(	NULL
10-100	NULL
ng/mL	NULL
)	NULL
.	NULL

IL-6	NULL
did	NULL
not	NULL
abrogate	NULL
TRAIL-induced	NULL
apoptosis	NULL
of	NULL
S6B45	NULL
,	NULL
RPMI-8226/8	NULL
cells	NULL
,	NULL
or	NULL
MM-18	NULL
cells	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
,	NULL
even	NULL
at	NULL
IL-6	NULL
concentrations	NULL
2	NULL
logs	NULL
higher	NULL
than	NULL
those	NULL
shown	NULL
to	NULL
inhibit	NULL
apoptosis	NULL
in	NULL
these	NULL
MM	NULL
cells	NULL
.	NULL

Moreover	NULL
,	NULL
TRAIL	NULL
induced	NULL
apoptosis	NULL
of	NULL
S6B45	NULL
cells	NULL
,	NULL
which	NULL
constitutively	NULL
produce	NULL
IL-6	NULL
in	NULL
picogram	NULL
concentrations	NULL
(	NULL
<	NULL
10	NULL
pg/mL	NULL
)	NULL
.	NULL
``	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
IL-6	NULL
is	NULL
not	NULL
a	NULL
pathophysiologi-	NULL
TRAIL/Apo2L-INDUCED	NULL
APOPTOSIS	NULL
OF	NULL
MULTIPLE	NULL
MYELOMA	NULL
CELLS	NULL
-	NULL
799	NULL
cally	NULL
significant	NULL
modulator	NULL
of	NULL
TRAIL-induced	NULL
apoptosis	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
its	NULL
documented	NULL
role	NULL
in	NULL
protecting	NULL
MM	NULL
cells	NULL
against	NULL
Dex-induced	NULL
apoptosis.2*	NULL
``	NULL
8	NULL
TRAIL	NULL
receptor	NULL
expression	NULL
in	NULL
MM	NULL
cell	NULL
lines	NULL
We	NULL
investigated	NULL
whether	NULL
differences	NULL
in	NULL
MM	NULL
cell	NULL
sensitivity	NULL
to	NULL
TRAIL	NULL
correlate	NULL
with	NULL
variations	NULL
in	NULL
expression	NULL
of	NULL
TRAIL	NULL
receptors	NULL
by	NULL
performing	NULL
immunoblotting	NULL
of	NULL
MM	NULL
cell	NULL
lysates	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
and	NULL
flow	NULL
cytometric	NULL
analysis	NULL
to	NULL
detect	NULL
surface	NULL
expression	NULL
of	NULL
receptors	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

Immunoblotting	NULL
analysis	NULL
of	NULL
10	NULL
MM	NULL
cell	NULL
lines	NULL
(	NULL
MM-AS	NULL
,	NULL
MM-SV	NULL
,	NULL
MM-1	NULL
8	NULL
,	NULL
U266	NULL
,	NULL
RPMI-8226/S	NULL
,	NULL
$	NULL
6B45	NULL
,	NULL
OCI	NULL
My-5	NULL
,	NULL
ARH-77	NULL
,	NULL
HS	NULL
Sultan	NULL
,	NULL
and	NULL
IMQ	NULL
)	NULL
demonstrated	NULL
expression	NULL
of	NULL
all	NULL
4	NULL
receptors	NULL
in	NULL
all	NULL
MM	NULL
lines	NULL
(	NULL
including	NULL
high	NULL
levels	NULL
of	NULL
DR5	NULL
and	NULL
DcR2	NULL
in	NULL
all	NULL
lines	NULL
and	NULL
variable	NULL
DR4	NULL
and	NULL
DcR1	NULL
expression	NULL
)	NULL
,	NULL
regardless	NULL
of	NULL
their	NULL
TRAIL	NULL
sensitivity	NULL
status	NULL
.	NULL

Some	NULL
TRAIL-resistant	NULL
lines	NULL
(	NULL
eg	NULL
,	NULL
ARH-77	NULL
,	NULL
HS	NULL
A	NULL
120	NULL
100	NULL
7	NULL
E	NULL
80	NULL
{	NULL
E	NULL
60	NULL
e	NULL
&	NULL
ao	NULL
g	NULL
o	NULL
x	NULL
1	NULL
20	NULL
0	NULL
C	NULL
<	NULL
/	NULL
p	NULL
4	NULL
<	NULL
096-0	NULL
,	NULL
ﬁqla	NULL
(	NULL
6:10	NULL
021	NULL
,	NULL
3/0	NULL
{	NULL
cg/0	NULL
l	NULL
ec	NULL
e	NULL
n	NULL
*	NULL
``	NULL
o	NULL
*	NULL
*	NULL
,	NULL
``	NULL
,	NULL
*	NULL
7	NULL
x	NULL
¢	NULL
€	NULL
,	NULL
3437	NULL
2	NULL
``	NULL
o	NULL
°	NULL
,	NULL
b	NULL
4	NULL
*	NULL
Ces	NULL
B	NULL
C4	NULL
5	NULL
7	NULL
MM-1S8	NULL
+	NULL
IL-6	NULL
1	NULL
(	NULL
85.9	NULL
%	NULL
)	NULL
--	NULL
-	NULL
(	NULL
eh	NULL
[	NULL
@	NULL
D	NULL
a	NULL
LL	NULL
1023	NULL
PI	NULL
Figure	NULL
5	NULL
.	NULL

Lack	NULL
of	NULL
IL-6	NULL
rescue	NULL
on	NULL
TRAIL-induced	NULL
MM	NULL
cell	NULL
death	NULL
.	NULL

MTT	NULL
colorimetric	NULL
assay	NULL
(	NULL
A	NULL
)	NULL
and	NULL
PI	NULL
staining	NULL
(	NULL
B	NULL
)	NULL
,	NULL
performed	NULL
in	NULL
MM-1S	NULL
cells	NULL
cultured	NULL
with	NULL
TRAIL	NULL
(	NULL
1000	NULL
ng/mL	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
,	NULL
document	NULL
that	NULL
IL-6	NULL
does	NULL
not	NULL
abrogate	NULL
TRAIL-induced	NULL
cell	NULL
death	NULL
.	NULL

In	NULL
panel	NULL
B	NULL
,	NULL
the	NULL
shaded	NULL
cell	NULL
cycle	NULL
profile	NULL
corresponds	NULL
to	NULL
MM-15	NULL
cells	NULL
cultured	NULL
with	NULL
IL-6	NULL
.	NULL

The	NULL
unshaded	NULL
profile	NULL
,	NULL
corresponding	NULL
to	NULL
cells	NULL
treated	NULL
with	NULL
TRAIL	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-6	NULL
,	NULL
is	NULL
identical	NULL
to	NULL
the	NULL
one	NULL
of	NULL
MM-1S	NULL
cells	NULL
treated	NULL
with	NULL
TRAIL	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

800	NULL
_	NULL
MITSIADES	NULL
etal	NULL
DR4	NULL
DRS	NULL
DeR1	NULL
P-	NULL
``	NULL
ﬂ—H	NULL
Tubulin	NULL
(	NULL
~	NULL
~-	NULL
--	NULL
-	NULL
*~	NULL
P	NULL
ps	NULL
w	NULL
pee	NULL
-up	NULL
<	NULL
--	NULL
>	NULL
mgp	NULL
|	NULL
\t	NULL
``	NULL
K	NULL
ie	NULL
Figure	NULL
6	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
TRAIL	NULL
receptor	NULL
expression	NULL
in	NULL
MM	NULL
and	NULL
NHL	NULL
B-cell	NULL
lines	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
for	NULL
DR4	NULL
and	NULL
DRS	NULL
death-signaling	NULL
and	NULL
DcR1	NULL
and	NULL
DcR2	NULL
``	NULL
decoy	NULL
``	NULL
TRAIL	NULL
receptors	NULL
was	NULL
performed	NULL
in	NULL
lysates	NULL
derived	NULL
from	NULL
10	NULL
MM	NULL
cell	NULL
lines	NULL
(	NULL
MM-AS	NULL
,	NULL
MM-SV	NULL
,	NULL
MM-1S	NULL
,	NULL
U266	NULL
,	NULL
RPMI-8226/S	NULL
,	NULL
S6B45	NULL
,	NULL
OCI	NULL
My-5	NULL
,	NULL
ARH-77	NULL
,	NULL
HS	NULL
Sultan	NULL
,	NULL
and	NULL
IM-9	NULL
)	NULL
and	NULL
2	NULL
NHL	NULL
B-cell	NULL
lines	NULL
(	NULL
DHL-4	NULL
and	NULL
DHL-10	NULL
)	NULL
.	NULL

SK-N-MC	NULL
Ewing	NULL
sarcoma	NULL
cells	NULL
served	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

Tubulin	NULL
detection	NULL
was	NULL
used	NULL
to	NULL
confirm	NULL
equal	NULL
protein	NULL
loading	NULL
.	NULL

Sultan	NULL
,	NULL
and	NULL
IM-9	NULL
)	NULL
appeared	NULL
to	NULL
have	NULL
high	NULL
expression	NULL
of	NULL
DcR1	NULL
by	NULL
immunoblotting	NULL
.	NULL

However	NULL
,	NULL
several	NULL
TRAIL-sensitive	NULL
lines	NULL
(	NULL
eg	NULL
,	NULL
MM-18	NULL
,	NULL
U266	NULL
,	NULL
and	NULL
OCI-My5	NULL
)	NULL
also	NULL
had	NULL
high	NULL
levels	NULL
of	NULL
DcR1	NULL
expression	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
DcR1	NULL
status	NULL
can	NULL
not	NULL
serve	NULL
to	NULL
predict	NULL
TRAIL	NULL
sensitivity	NULL
or	NULL
resistance	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
whereas	NULL
surface	NULL
expression	NULL
(	NULL
by	NULL
flow	NULL
cytometry	NULL
)	NULL
was	NULL
also	NULL
positive	NULL
in	NULL
all	NULL
lines	NULL
for	NULL
DR5	NULL
and	NULL
DcR2	NULL
,	NULL
it	NULL
was	NULL
negative	NULL
for	NULL
DcR1	NULL
(	NULL
for	NULL
all	NULL
3	NULL
different	NULL
antihuman	NULL
DcR1	NULL
antibodies	NULL
tested	NULL
)	NULL
,	NULL
excluding	NULL
any	NULL
correlation	NULL
of	NULL
these	NULL
parameters	NULL
with	NULL
TRAIL	NULL
sensitivity	NULL
.	NULL

Although	NULL
2	NULL
TRALIL-resistant	NULL
lines	NULL
(	NULL
ARH-77	NULL
and	NULL
IM-9	NULL
)	NULL
had	NULL
absent	NULL
or	NULL
dimly	NULL
positive	NULL
surface	NULL
DR4	NULL
expression	NULL
(	NULL
despite	NULL
high	NULL
levels	NULL
of	NULL
expression	NULL
in	NULL
Western	NULL
blots	NULL
)	NULL
,	NULL
other	NULL
TRAIL-resistant	NULL
cells	NULL
(	NULL
eg	NULL
,	NULL
HS	NULL
Sultan	NULL
;	NULL
Figure	NULL
7	NULL
)	NULL
had	NULL
strong	NULL
surface	NULL
expression	NULL
of	NULL
DR4	NULL
receptors	NULL
,	NULL
whereas	NULL
no	NULL
correlation	NULL
was	NULL
noted	NULL
between	NULL
lack	NULL
of	NULL
surface	NULL
DR4	NULL
expression	NULL
and	NULL
TRAIL	NULL
resistance	NULL
in	NULL
our	NULL
panel	NULL
of	NULL
MM	NULL
cell	NULL
lines	NULL
(	NULL
McNemar	NULL
paired	NULL
x	NULL
test	NULL
,	NULL
P	NULL
=	NULL
.25	NULL
)	NULL
.	NULL

Although	NULL
some	NULL
TRAIL-sensitive	NULL
MM	NULL
cells	NULL
(	NULL
eg	NULL
,	NULL
RPMI-8226/8	NULL
)	NULL
had	NULL
higher	NULL
levels	NULL
of	NULL
surface	NULL
DR5	NULL
expression	NULL
than	NULL
the	NULL
TRAIL-resistant	NULL
ARH-77	NULL
or	NULL
IM-9	NULL
cells	NULL
,	NULL
our	NULL
panel	NULL
of	NULL
cell	NULL
lines	NULL
included	NULL
both	NULL
strongly	NULL
surface	NULL
DR5+*	NULL
TRAIL-resistant	NULL
cells	NULL
(	NULL
eg	NULL
,	NULL
HS	NULL
Sultan	NULL
cells	NULL
)	NULL
and	NULL
weakly	NULL
DR5*	NULL
TRAIL-sensitive	NULL
cells	NULL
.	NULL

This	NULL
indicates	NULL
lack	NULL
of	NULL
correlation	NULL
between	NULL
the	NULL
levels	NULL
of	NULL
DR5	NULL
expression	NULL
with	NULL
TRAIL	NULL
sensitivity	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
status	NULL
of	NULL
signaling	NULL
or	NULL
``	NULL
decoy	NULL
``	NULL
TRAIL	NULL
receptors	NULL
,	NULL
assessed	NULL
using	NULL
either	NULL
immunoblotting	NULL
analysis	NULL
or	NULL
flow	NULL
cytometry	NULL
,	NULL
can	NULL
not	NULL
serve	NULL
to	NULL
reliably	NULL
predict	NULL
the	NULL
TRAIL	NULL
sensitivity	NULL
(	NULL
or	NULL
resistance	NULL
)	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

Dox	NULL
enhances	NULL
the	NULL
in	NULL
vitro	NULL
proapoptotic	NULL
effect	NULL
of	NULL
TRAIL	NULL
on	NULL
MM	NULL
cells	NULL
We	NULL
next	NULL
determined	NULL
whether	NULL
the	NULL
cytotoxic	NULL
agent	NULL
Dox	NULL
enhanced	NULL
the	NULL
proapoptotic	NULL
effect	NULL
of	NULL
TRAIL	NULL
in	NULL
TRAIL-sensitive	NULL
and	NULL
TRAIL-resistant	NULL
MM	NULL
cells	NULL
,	NULL
because	NULL
Dox	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
enhance	NULL
the	NULL
apoptotic	NULL
activity	NULL
of	NULL
TRAIL	NULL
and	NULL
up-regulate	NULL
the	NULL
DR5	NULL
receptor	NULL
in	NULL
MCF-7	NULL
breast	NULL
cancer	NULL
cells	NULL
.	NULL

``	NULL
°	NULL
MM-18	NULL
,	NULL
MM-1R	NULL
,	NULL
RPMI-8226/8	NULL
,	NULL
and	NULL
RPMI-8226/Dox40	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
Dox	NULL
(	NULL
250	NULL
or	NULL
500	NULL
ng/mL	NULL
.	NULL
)	NULL

for	NULL
4	NULL
hours	NULL
,	NULL
and	NULL
then	NULL
exposed	NULL
to	NULL
LZ-TRAIL	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
for	NULL
18	NULL
hours	NULL
.	NULL

MTT	NULL
assays	NULL
(	NULL
Figure	NULL
8	NULL
)	NULL
revealed	NULL
that	NULL
Dox	NULL
significantly	NULL
enhanced	NULL
the	NULL
proapoptotic	NULL
effect	NULL
of	NULL
TRAIL	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
reducing	NULL
BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
their	NULL
survival	NULL
to	NULL
levels	NULL
lower	NULL
than	NULL
expected	NULL
if	NULL
Dox	NULL
and	NULL
TRAIL	NULL
had	NULL
an	NULL
additive	NULL
interaction	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
,	NULL
for	NULL
each	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
and	NULL
flow	NULL
cytometry	NULL
revealed	NULL
that	NULL
a	NULL
24-hour	NULL
exposure	NULL
of	NULL
MM-18	NULL
cells	NULL
to	NULL
Dox	NULL
(	NULL
250	NULL
and	NULL
500	NULL
ng/mL	NULL
)	NULL
induced	NULL
a	NULL
significant	NULL
dose-dependent	NULL
up-regulation	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
DR5	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
of	NULL
DeR1	NULL
,	NULL
but	NULL
not	NULL
of	NULL
DR4	NULL
TRAIL	NULL
receptor	NULL
,	NULL
whereas	NULL
a	NULL
modest	NULL
decrease	NULL
of	NULL
DeR2	NULL
expression	NULL
was	NULL
also	NULL
noted	NULL
(	NULL
Figure	NULL
9	NULL
)	NULL
.	NULL

NF-B	NULL
inhibition	NULL
or	NULL
proteasome	NULL
inhibition	NULL
modulate	NULL
the	NULL
effect	NULL
of	NULL
TRAIL	NULL
on	NULL
MM	NULL
cells	NULL
Because	NULL
NF-KB	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
MM	NULL
cell	NULL
survival	NULL
,	NULL
``	NULL
we	NULL
investigated	NULL
whether	NULL
inhibition	NULL
of	NULL
NF-KB	NULL
transcriptional	NULL
activity	NULL
could	NULL
modulate	NULL
the	NULL
response	NULL
of	NULL
MM	NULL
cells	NULL
to	NULL
TRAIL	NULL
.	NULL

MM-18	NULL
and	NULL
RPMI-8226/8	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
TRAIL-resistant	NULL
ARH-77	NULL
and	NULL
IM-9	NULL
cells	NULL
,	NULL
were	NULL
pretreated	NULL
for	NULL
4	NULL
hours	NULL
with	NULL
a	NULL
nontoxic	NULL
concentration	NULL
(	NULL
30	NULL
ng/mL	NULL
)	NULL
of	NULL
the	NULL
cell-permeable	NULL
peptide	NULL
SN50	NULL
or	NULL
with	NULL
its	NULL
mutant	NULL
control	NULL
peptide	NULL
SN5O0M	NULL
.	NULL

SN50	NULL
binds	NULL
to	NULL
the	NULL
nuclear	NULL
localization	NULL
sequence	NULL
of	NULL
NF-KB	NULL
and	NULL
blocks	NULL
its	NULL
nuclear	NULL
translocation	NULL
,	NULL
thus	NULL
inhibiting	NULL
its	NULL
transcriptional	NULL
activity	NULL
.	NULL
``	NULL

As	NULL
seen	NULL
in	NULL
Figure	NULL
10	NULL
,	NULL
SN50	NULL
pretreatment	NULL
enhanced	NULL
the	NULL
sensitivity	NULL
of	NULL
MM-15	NULL
cells	NULL
(	NULL
<	NULL
5	NULL
%	NULL
survival	NULL
)	NULL
to	NULL
TRAIL	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
pretreatment	NULL
of	NULL
MM-18	NULL
with	NULL
the	NULL
mutant	NULL
control	NULL
peptide	NULL
SNOM	NULL
(	NULL
which	NULL
led	NULL
to	NULL
>	NULL
50	NULL
%	NULL
survival	NULL
of	NULL
MM-18	NULL
cells	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
SN50	NULL
also	NULL
reversed	NULL
the	NULL
TRAIL	NULL
resistance	NULL
of	NULL
ARH-77	NULL
and	NULL
IM-9	NULL
cells	NULL
(	NULL
Figure	NULL
10C	NULL
,	NULL
D	NULL
)	NULL
;	NULL
SN-50	NULL
pretreatment	NULL
and	NULL
TRAIL	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
led	NULL
to	NULL
less	NULL
than	NULL
60	NULL
%	NULL
survival	NULL
of	NULL
these	NULL
cells	NULL
,	NULL
whereas	NULL
these	NULL
cells	NULL
were	NULL
resistant	NULL
even	NULL
to	NULL
1000	NULL
ng/mL	NULL
TRAIL	NULL
without	NULL
SN50	NULL
pretreatment	NULL
.	NULL

We	NULL
also	NULL
determined	NULL
whether	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
PS-341	NULL
,	NULL
DeRI1	NULL
DeR2	NULL
lla	NULL
k	NULL
la	NULL
#	NULL
a	NULL
&	NULL
#	NULL
#	NULL
RPMI-8226/S	NULL
i	NULL
it	NULL
g	NULL
‘	NULL
J	NULL
El	NULL
F	NULL
£	NULL
,	NULL
&	NULL
=	NULL
a	NULL
ARH-77	NULL
i	NULL
£	NULL
1A	NULL
E	NULL
f	NULL
E	NULL
?	NULL

§	NULL
=	NULL
&	NULL
HS	NULL
Sultan	NULL
_	NULL
;	NULL
:	NULL
f	NULL
I	NULL
”	NULL
f	NULL
f	NULL
B	NULL
gt	NULL
Figure	NULL
7	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
for	NULL
TRAIL	NULL
receptor	NULL
expression	NULL
in	NULL
MM	NULL
cell	NULL
lines	NULL
.	NULL

Flow	NULL
cytometric	NULL
analyses	NULL
for	NULL
surface	NULL
TRAIL	NULL
receptors	NULL
'	NULL
expression	NULL
in	NULL
5	NULL
representative	NULL
cell	NULL
lines	NULL
(	NULL
the	NULL
TRAIL-sensitive	NULL
MM-15	NULL
and	NULL
RPMI-8226/S	NULL
cells	NULL
and	NULL
the	NULL
TRAIL-resistant	NULL
ARH-7	NULL
,	NULL
IM-9	NULL
,	NULL
and	NULL
HS	NULL
Sultan	NULL
cells	NULL
)	NULL
indicates	NULL
that	NULL
the	NULL
status	NULL
of	NULL
neither	NULL
the	NULL
TRAIL-signaling	NULL
DR4	NULL
and	NULL
DRS	NULL
nor	NULL
the	NULL
``	NULL
decoy	NULL
``	NULL
DeR1	NULL
and	NULL
DcR2Z	NULL
receptors	NULL
can	NULL
serve	NULL
to	NULL
predict	NULL
the	NULL
TRAIL	NULL
sensitivity	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

The	NULL
depicted	NULL
graphs	NULL
were	NULL
obtained	NULL
after	NULL
staining	NULL
with	NULL
antihuman	NULL
DR4	NULL
,	NULL
DRS	NULL
,	NULL
DcR1	NULL
,	NULL
and	NULL
DcR2	NULL
mAbs	NULL
(	NULL
Genentech	NULL
)	NULL
and	NULL
confirmed	NULL
by	NULL
use	NULL
of	NULL
the	NULL
other	NULL
anti-	NULL
T	NULL
RAIL	NULL
receptor	NULL
antibodies	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL
``	NULL

Shaded	NULL
curves	NULL
depict	NULL
isotype	NULL
control	NULL
staining	NULL
,	NULL
and	NULL
unshaded	NULL
peaks	NULL
correspond	NULL
to	NULL
staining	NULL
with	NULL
the	NULL
respective	NULL
TRAIL	NULL
receptor	NULL
antibodies	NULL
.	NULL

is	NULL
is	NULL
IM-9	NULL
bm	NULL
me	NULL
bee	NULL
taas	NULL
o	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
120	NULL
120	NULL
100	NULL
100	NULL
E	NULL
80	NULL
T	NULL
;	NULL
80	NULL
&	NULL
so	NULL
E	NULL
5	NULL
5	NULL
60	NULL
un	NULL
EA	NULL
®	NULL
40	NULL
®	NULL
40	NULL
20	NULL
20	NULL
0	NULL
0	NULL
b	NULL
t	NULL
t.	NULL
*	NULL
%	NULL
4	NULL
b	NULL
t	NULL
t	NULL
a	NULL
t	NULL
,	NULL
t	NULL
2	NULL
t/	NULL
y	NULL
o	NULL
y	NULL
``	NULL
5	NULL
090/ny	NULL
oy	NULL
ty	NULL
y	NULL
``	NULL
op	NULL
t	NULL
t	NULL
%	NULL
*	NULL
t	NULL
%	NULL
%	NULL
%	NULL
*	NULL
”	NULL
(	NULL
X	NULL
)	NULL
”	NULL
?	NULL

Qﬂ	NULL
)	NULL
*	NULL
*	NULL
)	NULL
*t	NULL
*t	NULL
,	NULL
2	NULL
,	NULL
7	NULL
,	NULL
Ce	NULL
*to	NULL
-	NULL
*	NULL
%	NULL
RPMI-8226	NULL
RPMI-Dox40	NULL
120	NULL
120	NULL
100	NULL
100	NULL
€	NULL
so	NULL
T	NULL
so	NULL
3	NULL
€	NULL
&	NULL
®	NULL
&	NULL
®	NULL
x	NULL
40	NULL
y	NULL
40	NULL
20	NULL
20	NULL
0	NULL
0	NULL
G	NULL
o	NULL
&	NULL
,	NULL
e	NULL
4	NULL
,	NULL
+4	NULL
GOQU/	NULL
Q1	NULL
?	NULL

*	NULL
»	NULL
Q	NULL
‘	NULL
fr	NULL
$	NULL
030	NULL
$	NULL
50	NULL
*	NULL
,	NULL
a	NULL
?	NULL

?	NULL

?	NULL

049	NULL
09,69	NULL
aﬁr	NULL
00,5	NULL
n	NULL
toto	NULL
G	NULL
&	NULL
»	NULL
%	NULL
%	NULL
*	NULL
%	NULL
‘	NULL
%	NULL
,	NULL
<	NULL
“	NULL
$	NULL
4	NULL
?	NULL

QQ	NULL
“	NULL
b	NULL
?	NULL

94a	NULL
,	NULL
»	NULL
t	NULL
to	NULL
*	NULL
,	NULL
x	NULL
?	NULL

?	NULL

?	NULL

*	NULL
,	NULL
k	NULL
*	NULL
,	NULL
*	NULL
*	NULL
,	NULL
a	NULL
**	NULL
*z	NULL
-	NULL
*	NULL
%	NULL
Figure	NULL
8	NULL
.	NULL

Doxorubicin	NULL
sensitizes	NULL
Dex-sensitive	NULL
(	NULL
MM-19	NULL
)	NULL
and	NULL
Dex-resistant	NULL
(	NULL
MM-1R	NULL
)	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
Dox-sensitive	NULL
(	NULL
RPMI-8226/S	NULL
)	NULL
and	NULL
Dox-resistant	NULL
(	NULL
Dox40	NULL
)	NULL
cells	NULL
,	NULL
to	NULL
TRAIL	NULL
.	NULL

MTT	NULL
colorimetric	NULL
assays	NULL
demonstrate	NULL
that	NULL
pretreatment	NULL
with	NULL
Dox	NULL
,	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
methods	NULL
,	NULL
``	NULL
enhances	NULL
the	NULL
TRAIL	NULL
sensitivity	NULL
of	NULL
MM	NULL
cells	NULL
,	NULL
including	NULL
MM	NULL
cells	NULL
resistant	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
Dex	NULL
(	NULL
MM-1	NULL
R	NULL
)	NULL
or	NULL
Dox	NULL
(	NULL
Dox40	NULL
)	NULL
.	NULL

which	NULL
is	NULL
known	NULL
to	NULL
inhibit	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF-kB	NULL
by	NULL
blocking	NULL
the	NULL
degradation	NULL
of	NULL
the	NULL
IxB	NULL
inhibitory	NULL
protein	NULL
,	NULL
``	NULL
sensitized	NULL
MM	NULL
cells	NULL
to	NULL
TRAIL-induced	NULL
apoptosis	NULL
.	NULL

MM-18	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
0.1	NULL
M	NULL
PS-341	NULL
for	NULL
3	NULL
hours	NULL
and	NULL
then	NULL
exposed	NULL
to	NULL
TRAIL	NULL
i	NULL
i	NULL
smmmmmmmmee	NULL
>	NULL
|	NULL
DR4	NULL
DRS	NULL
@	NULL
-	NULL
Mp	NULL
r	NULL
:	NULL
~	NULL
,	NULL
a	NULL
~~	NULL
Fe-	NULL
DeR2	NULL
r	NULL
“	NULL
.	NULL

~a	NULL
,	NULL
0	NULL
)	NULL
.	NULL

0	NULL
o	NULL
To	NULL
T7	NULL
6	NULL
930	NULL
``	NULL
$	NULL
00	NULL
Ue	NULL
o	NULL
.	NULL

(	NULL
6	NULL
)	NULL
,	NULL
4/0	NULL
?	NULL

B	NULL
C	NULL
&	NULL
&	NULL
SP	NULL
e	NULL
MM-18	NULL
control	NULL
*	NULL
MM-18	NULL
$	NULL
Doxorubicin	NULL
``	NULL
ﬁt	NULL
(	NULL
ceo	NULL
)	NULL
i	NULL
I	NULL
'	NULL
Hell	NULL
222220	NULL
t	NULL
#	NULL
J	NULL
A	NULL
\	NULL
a	NULL
31	NULL
[	NULL
{	NULL
]	NULL
p	NULL
d	NULL
A	NULL
|	NULL
d	NULL
(	NULL
J	NULL
|	NULL
\	NULL
f	NULL
If	NULL
;	NULL
|	NULL
|	NULL
\A	NULL
#	NULL
:	NULL
_	NULL
C3	NULL
-n-	NULL
Time-	NULL
»	NULL
fr	NULL
m	NULL
mn	NULL
10°	NULL
10°	NULL
g	NULL
10°	NULL
10	NULL
%	NULL
10°	NULL
10	NULL
)	NULL
10+	NULL
k	NULL
10	NULL
ors	NULL
ors	NULL
Figure	NULL
9	NULL
.	NULL

Doxorubicin	NULL
up-regulates	NULL
DRS	NULL
expression	NULL
of	NULL
MM-1S	NULL
cells	NULL
.	NULL

Immunoblot	NULL
ting	NULL
analysis	NULL
(	NULL
A	NULL
)	NULL
of	NULL
Dox-treated	NULL
(	NULL
250	NULL
or	NULL
500	NULL
ng/mL	NULL
)	NULL
MM-1S	NULL
cells	NULL
reveals	NULL
dose-dependent	NULL
up-regulation	NULL
of	NULL
DRS	NULL
expression	NULL
,	NULL
confirmed	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Dox	NULL
also	NULL
induces	NULL
a	NULL
small	NULL
increase	NULL
in	NULL
DcR1	NULL
and	NULL
decrease	NULL
in	NULL
DcRZ	NULL
expression	NULL
,	NULL
by	NULL
immunoblotting	NULL
analysis	NULL
(	NULL
A	NULL
)	NULL
.	NULL

TRAIL/Apo2L-INDUCED	NULL
APOPTOSIS	NULL
OF	NULL
MULTIPLE	NULL
MYELOMA	NULL
CELLS	NULL
_	NULL
801	NULL
A..	NULL
MM-18S	NULL
B	NULL
-	NULL
RPMI-8	NULL
$	NULL
226/S	NULL
a	NULL
«	NULL
20	NULL
h	NULL
&	NULL
B	NULL
a	NULL
an	NULL
®	NULL
we	NULL
a	NULL
s	NULL
P	NULL
3	NULL
H	NULL
bobs	NULL
)	NULL
.	NULL

-	NULL
$	NULL
1112	NULL
:	NULL
£5172	NULL
:	NULL
Control	NULL
-	NULL
TRAIL	NULL
”	NULL
$	NULL
35	NULL
.N	NULL
:	NULL
.	NULL

:	NULL
.E	NULL
+TRAIL	NULL
inhibitor	NULL
IszAIZ-r	NULL
C	NULL
ARH-77	NULL
D	NULL
IM-9	NULL
120	NULL
120	NULL
100	NULL
,	NULL
10	NULL
F	NULL
a	NULL
¢	NULL
®	NULL
f	NULL
.	NULL

i	NULL
s	NULL
a	NULL
a	NULL
#	NULL
®	NULL
z	NULL
«	NULL
a	NULL
20	NULL
m	NULL
|	NULL
I	NULL
¢	NULL
a	NULL
Control	NULL
TRAIL	NULL
NF	NULL
«	NULL
B	NULL
NFkB	NULL
Control	NULL
TRAIL	NULL
NFkB	NULL
NFKB	NULL
inhibitor	NULL
.	NULL

inhibitor	NULL
mmibiter	NULL
.	NULL

Wiikker	NULL
+TRAIL	NULL
Sk	NULL
Figure	NULL
10	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
augments	NULL
TRAIL	NULL
sensitivity	NULL
or	NULL
reverses	NULL
TRAIL	NULL
resistance	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

MT	NULL
T	NULL
colorimetric	NULL
assays	NULL
indicate	NULL
that	NULL
pretreatment	NULL
with	NULL
the	NULL
NF-kB	NULL
inhibitory	NULL
peptide	NULL
SN50	NULL
enhances	NULL
TRAIL	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
-induced	NULL
cell	NULL
death	NULL
in	NULL
TRAIL-sensitive	NULL
MM-1S	NULL
and	NULL
RPMI-8226/S	NULL
cells	NULL
(	NULL
A	NULL
,	NULL
B	NULL
)	NULL
and	NULL
overcomes	NULL
the	NULL
TRAIL	NULL
resistance	NULL
of	NULL
ARH-77	NULL
and	NULL
IM-9	NULL
cells	NULL
(	NULL
C	NULL
and	NULL
D	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

(	NULL
50	NULL
or	NULL
100	NULL
ng/mL	NULL
)	NULL
for	NULL
18	NULL
hours	NULL
.	NULL

These	NULL
studies	NULL
demonstrated	NULL
that	NULL
PS-341	NULL
preincubation	NULL
augmented	NULL
the	NULL
sensitivity	NULL
of	NULL
MM-1S	NULL
cells	NULL
to	NULL
TRAIL	NULL
(	NULL
Figure	NULL
11	NULL
)	NULL
.	NULL

Normal	NULL
B	NULL
cells	NULL
are	NULL
not	NULL
sensitized	NULL
to	NULL
TRAIL	NULL
by	NULL
either	NULL
Dox	NULL
,	NULL
PS-341	NULL
,	NULL
or	NULL
NF-xB	NULL
inhibition	NULL
We	NULL
next	NULL
investigated	NULL
whether	NULL
pretreatment	NULL
of	NULL
TRAIL-resistant	NULL
healthy	NULL
donor	NULL
B	NULL
cells	NULL
with	NULL
Dox	NULL
,	NULL
PS-341	NULL
,	NULL
or	NULL
SN50	NULL
similarly	NULL
sensitized	NULL
these	NULL
cells	NULL
to	NULL
TRAIL	NULL
.	NULL

Pretreatment	NULL
with	NULL
either	NULL
Dox	NULL
or	NULL
agents	NULL
that	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
did	NULL
not	NULL
sensitize	NULL
normal	NULL
B	NULL
cells	NULL
or	NULL
PBMCs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
to	NULL
TRAIL	NULL
.	NULL

Importantly	NULL
,	NULL
in	NULL
the	NULL
context	NULL
of	NULL
these	NULL
pretreatments	NULL
,	NULL
B	NULL
cells	NULL
remained	NULL
refractory	NULL
to	NULL
TRAIL	NULL
at	NULL
doses	NULL
up	NULL
to	NULL
300	NULL
ng/mL	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
MM	NULL
cells	NULL
,	NULL
which	NULL
were	NULL
sensitized	NULL
by	NULL
these	NULL
pretreatments	NULL
at	NULL
doses	NULL
of	NULL
TRAIL	NULL
as	NULL
low	NULL
as	NULL
50	NULL
ng/mL	NULL
.	NULL

Effect	NULL
of	NULL
TRAIL	NULL
on	NULL
established	NULL
human	NULL
plasmacytomas	NULL
in	NULL
xenografted	NULL
nu/xid/bg	NULL
mice	NULL
We	NULL
next	NULL
examined	NULL
whether	NULL
TRAIL	NULL
was	NULL
active	NULL
against	NULL
MM	NULL
in	NULL
vivo	NULL
by	NULL
treating	NULL
established	NULL
human	NULL
plasmacytomas	NULL
in	NULL
nu/xid/bg	NULL
mice	NULL
with	NULL
either	NULL
TRAIL	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
or	NULL
PBS	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
.	NULL

Mean	NULL
plasmacytoma	NULL
volumes	NULL
were	NULL
not	NULL
significantly	NULL
different	NULL
at	NULL
initiation	NULL
of	NULL
therapy	NULL
on	NULL
120	NULL
100	NULL
o	NULL
II	NULL
-I	NULL
mH	NULL
_	NULL
Control	NULL
-	NULL
PS-341	NULL
0.1	NULL
TRAIL	NULL
50	NULL
-	NULL
PS-341	NULL
_	NULL
TRAIL	NULL
-	NULL
PS-341	NULL
+	NULL
pM	NULL
-__	NULL
ng/mL	NULL
-	NULL
+TRAIL	NULL
100	NULL
ng/mL	NULL
TRAIL	NULL
50	NULL
ng/mL	NULL
100	NULL
ng/mL	NULL
%	NULL
Survival	NULL
Figure	NULL
11	NULL
.	NULL

The	NULL
proteasome	NULL
inhibitor	NULL
PS-341	NULL
enhances	NULL
the	NULL
TRAIL	NULL
sensitivity	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

Pretreatment	NULL
of	NULL
MM-15	NULL
cells	NULL
with	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
PS-341	NULL
(	NULL
0.1	NULL
M	NULL
)	NULL
enhances	NULL
their	NULL
sensitivity	NULL
to	NULL
TRAIL	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
MT	NULL
T	NULL
colorimetric	NULL
assay	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

802	NULL
-	NULL
MITSIADES	NULL
etal	NULL
25000	NULL
--	NULL
@	NULL
-	NULL
PBS-treated	NULL
mice	NULL
-D-	NULL
TRAIL-treated	NULL
mice	NULL
20000	NULL
.	NULL

>	NULL
E	NULL
LZ-TRAIL	NULL
500	NULL
ug	NULL
ip	NULL
.	NULL

qd	NULL
<	NULL
15000	NULL
-	NULL
he	NULL
epe	NULL
4	NULL
|	NULL
E	NULL
3	NULL
g	NULL
>	NULL
&	NULL
10000	NULL
£	NULL
E	NULL
a	NULL
5000	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
12	NULL
14	NULL
16	NULL
18	NULL
20	NULL
Days	NULL
Figure	NULL
12	NULL
.	NULL

Effect	NULL
of	NULL
human	NULL
recombinant	NULL
LZ-T	NULL
RAIL	NULL
on	NULL
the	NULL
growth	NULL
of	NULL
established	NULL
human	NULL
plasmacytoma	NULL
xenografts	NULL
in	NULL
nu/xid/bg	NULL
mice	NULL
.	NULL

Nu/xid/bg	NULL
mice	NULL
were	NULL
injected	NULL
subcutaneously	NULL
with	NULL
human	NULL
S6B45	NULL
MM	NULL
cells	NULL
.	NULL

On	NULL
establishment	NULL
of	NULL
palpable	NULL
xenografts	NULL
,	NULL
the	NULL
mice	NULL
(	NULL
8/cohort	NULL
)	NULL
received	NULL
either	NULL
PBS	NULL
or	NULL
recombinant	NULL
human	NULL
LZ-T	NULL
RAIL	NULL
(	NULL
500	NULL
ug	NULL
intraperitoneally	NULL
daily	NULL
for	NULL
14	NULL
days	NULL
)	NULL
.	NULL

TRAIL	NULL
was	NULL
well	NULL
tolerated	NULL
by	NULL
the	NULL
mice	NULL
and	NULL
suppressed	NULL
the	NULL
growth	NULL
of	NULL
the	NULL
established	NULL
human	NULL
plasmacytomas	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
significant	NULL
increase	NULL
in	NULL
the	NULL
tumor	NULL
burden	NULL
generated	NULL
in	NULL
PBS-treated	NULL
control	NULL
mice	NULL
.	NULL

day	NULL
1	NULL
(	NULL
Figure	NULL
12	NULL
,	NULL
P	NULL
=.328	NULL
by	NULL
Mann-Whitney	NULL
test	NULL
)	NULL
.	NULL

Following	NULL
TRAIL	NULL
administration	NULL
,	NULL
the	NULL
volume	NULL
of	NULL
established	NULL
xenografts	NULL
did	NULL
not	NULL
show	NULL
a	NULL
significant	NULL
increase	NULL
from	NULL
baseline	NULL
(	NULL
P	NULL
=	NULL
.851	NULL
,	NULL
Kruskal-Wallis	NULL
nonparametric	NULL
one-way	NULL
analysis	NULL
of	NULL
variance	NULL
)	NULL
,	NULL
whereas	NULL
PBS-treated	NULL
mice	NULL
showed	NULL
increasing	NULL
mean	NULL
tumor	NULL
volumes	NULL
,	NULL
which	NULL
became	NULL
significantly	NULL
greater	NULL
than	NULL
baseline	NULL
beyond	NULL
day	NULL
8	NULL
(	NULL
P	NULL
<	NULL
.05	NULL
by	NULL
Kruskall-Wallis	NULL
test	NULL
)	NULL
.	NULL

Following	NULL
11	NULL
days	NULL
of	NULL
TRAIL	NULL
administration	NULL
,	NULL
the	NULL
mean	NULL
tumor	NULL
volumes	NULL
for	NULL
TRAIL-treated	NULL
mice	NULL
were	NULL
significantly	NULL
less	NULL
than	NULL
the	NULL
mean	NULL
tumor	NULL
volumes	NULL
for	NULL
mice	NULL
treated	NULL
with	NULL
PBS	NULL
(	NULL
P	NULL
=	NULL
.009	NULL
by	NULL
Mann-Whitney	NULL
test	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
complete	NULL
plasmacytoma	NULL
eradication	NULL
was	NULL
observed	NULL
in	NULL
1	NULL
of	NULL
8	NULL
TRAIL-treated	NULL
animals	NULL
on	NULL
day	NULL
11	NULL
.	NULL

Significantly	NULL
lower	NULL
mean	NULL
tumor	NULL
volumes	NULL
for	NULL
TRAIL-treated	NULL
versus	NULL
PBS-treated	NULL
mice	NULL
were	NULL
again	NULL
observed	NULL
on	NULL
day	NULL
14	NULL
(	NULL
P	NULL
=	NULL
.032	NULL
)	NULL
and	NULL
on	NULL
day	NULL
18	NULL
(	NULL
P	NULL
=	NULL
.046	NULL
)	NULL
.	NULL

However	NULL
,	NULL
on	NULL
day	NULL
18	NULL
(	NULL
4	NULL
days	NULL
following	NULL
termination	NULL
of	NULL
TRAIL	NULL
administration	NULL
)	NULL
,	NULL
the	NULL
mean	NULL
plasmacytoma	NULL
volume	NULL
in	NULL
TRAIL-treated	NULL
animals	NULL
increased	NULL
compared	NULL
to	NULL
the	NULL
baseline	NULL
mean	NULL
tumor	NULL
volume	NULL
for	NULL
these	NULL
animals	NULL
(	NULL
P	NULL
=	NULL
.006	NULL
)	NULL
,	NULL
yet	NULL
remained	NULL
significantly	NULL
less	NULL
than	NULL
that	NULL
in	NULL
PBS-treated	NULL
mice	NULL
.	NULL

On	NULL
day	NULL
18	NULL
,	NULL
the	NULL
PBS-treated	NULL
animals	NULL
were	NULL
moribund	NULL
and	NULL
all	NULL
animals	NULL
from	NULL
both	NULL
cohorts	NULL
were	NULL
euthanized	NULL
in	NULL
accordance	NULL
with	NULL
NIH	NULL
and	NULL
our	NULL
institutional	NULL
guidelines	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
xenografted	NULL
plasmacytoma	NULL
cells	NULL
remained	NULL
sensitive	NULL
to	NULL
TRAIL	NULL
despite	NULL
the	NULL
apparent	NULL
increase	NULL
in	NULL
tumor	NULL
volume	NULL
following	NULL
discontinuation	NULL
of	NULL
TRAIL	NULL
therapy	NULL
,	NULL
tumors	NULL
from	NULL
2	NULL
animals	NULL
were	NULL
excised	NULL
,	NULL
mechanically	NULL
dissociated	NULL
,	NULL
and	NULL
cultured	NULL
with	NULL
LZ-human	NULL
TRAIL	NULL
(	NULL
1000	NULL
ng/mL	NULL
)	NULL
for	NULL
24	NULL
hours	NULL
.	NULL

These	NULL
studies	NULL
demonstrated	NULL
that	NULL
the	NULL
excised	NULL
human	NULL
plasmacytomas	NULL
from	NULL
2	NULL
TRAIL-treated	NULL
mice	NULL
underwent	NULL
apoptosis	NULL
following	NULL
culture	NULL
with	NULL
TRAIL	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
PI	NULL
and	NULL
annexin	NULL
V	NULL
staining	NULL
.	NULL

Overall	NULL
,	NULL
mice	NULL
treated	NULL
with	NULL
TRAIL	NULL
tolerated	NULL
therapy	NULL
well	NULL
,	NULL
with	NULL
continued	NULL
display	NULL
of	NULL
weight	NULL
gain	NULL
throughout	NULL
therapy	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

One	NULL
TRAIL-treated	NULL
mouse	NULL
died	NULL
on	NULL
day	NULL
11	NULL
of	NULL
toxicity	NULL
not	NULL
related	NULL
to	NULL
TRAIL	NULL
(	NULL
intestinal	NULL
puncture	NULL
)	NULL
,	NULL
although	NULL
this	NULL
mouse	NULL
also	NULL
exhibited	NULL
a	NULL
tumor	NULL
response	NULL
to	NULL
TRAIL	NULL
therapy	NULL
.	NULL

Discussion	NULL
In	NULL
a	NULL
preliminary	NULL
report	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
TRAIL/ApoZL	NULL
induced	NULL
apoptosis	NULL
of	NULL
most	NULL
MM	NULL
cell	NULL
lines	NULL
and	NULL
MM	NULL
patient	NULL
tumor	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
a	NULL
finding	NULL
subsequently	NULL
confirmed	NULL
by	NULL
other	NULL
groups	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
In	NULL
BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
most	NULL
MM	NULL
cell	NULL
lines	NULL
,	NULL
including	NULL
those	NULL
that	NULL
are	NULL
resistant	NULL
to	NULL
Dex	NULL
and	NULL
chemotherapeutic	NULL
agents	NULL
,	NULL
are	NULL
sensitive	NULL
to	NULL
TRAIL/ApoZL	NULL
.	NULL

Moreover	NULL
,	NULL
TRAIL	NULL
induced	NULL
apoptosis	NULL
of	NULL
MM	NULL
cells	NULL
from	NULL
5	NULL
of	NULL
5	NULL
patients	NULL
and	NULL
did	NULL
not	NULL
affect	NULL
non-MM	NULL
BMMCs	NULL
,	NULL
normal	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
.	NULL

Importantly	NULL
,	NULL
IL-6	NULL
,	NULL
a	NULL
major	NULL
growth	NULL
and	NULL
survival	NULL
factor	NULL
of	NULL
MM	NULL
cells	NULL
,	NULL
blocks	NULL
apoptosis	NULL
induced	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
proapoptotic	NULL
agents	NULL
,	NULL
including	NULL
Dex	NULL
``	NULL
and	NULL
FasL	NULL
,	NULL
***°	NULL
but	NULL
does	NULL
not	NULL
abrogate	NULL
TRAIL-induced	NULL
apoptosis	NULL
.	NULL

The	NULL
differential	NULL
survival	NULL
effect	NULL
of	NULL
IL-6	NULL
in	NULL
protecting	NULL
from	NULL
FasL-induced	NULL
,	NULL
but	NULL
not	NULL
TRAIL-induced	NULL
,	NULL
apoptosis	NULL
may	NULL
reflect	NULL
differences	NULL
in	NULL
downstream	NULL
signaling	NULL
of	NULL
these	NULL
tumoricidal	NULL
TNF-related	NULL
cytokines	NULL
.	NULL

Detailed	NULL
analyses	NULL
of	NULL
our	NULL
panel	NULL
of	NULL
MM	NULL
cell	NULL
lines	NULL
for	NULL
TRAIL	NULL
receptor	NULL
expression	NULL
by	NULL
both	NULL
Western	NULL
blot	NULL
and	NULL
flow	NULL
cytometry	NULL
were	NULL
undertaken	NULL
to	NULL
discern	NULL
differences	NULL
that	NULL
might	NULL
confer	NULL
TRAIL	NULL
sensitivity	NULL
versus	NULL
resistance	NULL
.	NULL

The	NULL
death	NULL
signaling	NULL
receptors	NULL
DR4	NULL
and	NULL
DR5	NULL
were	NULL
expressed	NULL
in	NULL
all	NULL
MM	NULL
cell	NULL
lines	NULL
,	NULL
evidenced	NULL
by	NULL
both	NULL
Western	NULL
blot	NULL
and	NULL
flow	NULL
cytometric	NULL
analyses	NULL
,	NULL
except	NULL
for	NULL
the	NULL
TRAIL-resistant	NULL
ARH-77	NULL
and	NULL
IM-9	NULL
cell	NULL
lines	NULL
,	NULL
which	NULL
lack	NULL
surface	NULL
DR4	NULL
(	NULL
despite	NULL
strong	NULL
expression	NULL
by	NULL
immunoblotting	NULL
analysis	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
level	NULL
of	NULL
surface	NULL
expression	NULL
of	NULL
neither	NULL
DR4	NULL
nor	NULL
DR5	NULL
correlates	NULL
with	NULL
TRAIL-resistance	NULL
in	NULL
our	NULL
panel	NULL
of	NULL
MM	NULL
lines	NULL
;	NULL
some	NULL
TRAIL-resistant	NULL
cells	NULL
(	NULL
eg	NULL
,	NULL
HS	NULL
Sultan	NULL
)	NULL
had	NULL
very	NULL
strong	NULL
expression	NULL
of	NULL
both	NULL
receptors	NULL
,	NULL
in	NULL
comparison	NULL
to	NULL
some	NULL
TRAIL-sensitive	NULL
cells	NULL
(	NULL
eg	NULL
,	NULL
MM-18	NULL
)	NULL
.	NULL

Mutations	NULL
at	NULL
the	NULL
death	NULL
domain	NULL
of	NULL
the	NULL
DR5	NULL
receptor	NULL
have	NULL
been	NULL
described	NULL
in	NULL
other	NULL
neoplasias	NULL
``	NULL
*	NULL
``	NULL
and	NULL
could	NULL
also	NULL
account	NULL
for	NULL
TRAIL	NULL
resistance	NULL
in	NULL
cells	NULL
that	NULL
lack	NULL
surface	NULL
DR4	NULL
expression	NULL
,	NULL
such	NULL
as	NULL
ARH-77	NULL
and	NULL
IM-9	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
sensitize	NULL
these	NULL
cells	NULL
to	NULL
TRAIL	NULL
by	NULL
NF-B	NULL
inhibition	NULL
without	NULL
increasing	NULL
the	NULL
levels	NULL
of	NULL
DR4	NULL
or	NULL
DR5	NULL
(	NULL
N.	NULL
Mitsiades	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
the	NULL
baseline	NULL
levels	NULL
of	NULL
DR5	NULL
expression	NULL
in	NULL
these	NULL
MM	NULL
cells	NULL
are	NULL
sufficient	NULL
for	NULL
induction	NULL
of	NULL
apoptosis	NULL
within	NULL
the	NULL
context	NULL
of	NULL
appropriate	NULL
sensitization	NULL
stimuli	NULL
.	NULL

DcR1	NULL
and	NULL
DcR2	NULL
expression	NULL
has	NULL
been	NULL
suggested	NULL
as	NULL
another	NULL
potential	NULL
mechanism	NULL
for	NULL
protection	NULL
of	NULL
cells	NULL
against	NULL
TRAIL	NULL
;	NULL
therefore	NULL
,	NULL
we	NULL
also	NULL
investigated	NULL
whether	NULL
their	NULL
expression	NULL
correlated	NULL
with	NULL
TRAIL	NULL
resistance	NULL
in	NULL
MM	NULL
cells	NULL
.	NULL

DeR2	NULL
was	NULL
uniformly	NULL
expressed	NULL
on	NULL
all	NULL
MM	NULL
cells	NULL
(	NULL
both	NULL
TRAIL	NULL
sensitive	NULL
and	NULL
resistant	NULL
)	NULL
by	NULL
both	NULL
Western	NULL
blot	NULL
and	NULL
flow	NULL
cytometric	NULL
analyses	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
DcRI1	NULL
was	NULL
variably	NULL
expressed	NULL
on	NULL
MM	NULL
cell	NULL
lines	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
but	NULL
absent	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
by	NULL
flow	NULL
cytometry	NULL
performed	NULL
with	NULL
a	NULL
panel	NULL
of	NULL
3	NULL
anti-DcR1	NULL
antibodies	NULL
.	NULL

Therefore	NULL
,	NULL
TRAIL	NULL
receptor	NULL
status	NULL
alone	NULL
can	NULL
not	NULL
serve	NULL
as	NULL
a	NULL
reliable	NULL
predictor	NULL
of	NULL
TRAIL	NULL
sensitivity	NULL
in	NULL
MM	NULL
cells	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
lack	NULL
of	NULL
both	NULL
DR4	NULL
and	NULL
DR5	NULL
expression	NULL
.	NULL

This	NULL
latter	NULL
TRAIL	NULL
receptor	NULL
pattern	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
MM	NULL
cells	NULL
,	NULL
although	NULL
we	NULL
have	NULL
documented	NULL
it	NULL
in	NULL
other	NULL
neoplasias	NULL
.	NULL
``	NULL

''	NULL
This	NULL
lack	NULL
of	NULL
correlation	NULL
of	NULL
TRAIL	NULL
decoy	NULL
receptor	NULL
expression	NULL
with	NULL
TRAIL	NULL
sensitivity	NULL
in	NULL
MM	NULL
cells	NULL
observed	NULL
in	NULL
our	NULL
study	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
in	NULL
various	NULL
neoplasias*	NULL
``	NULL
**~	NULL
and	NULL
further	NULL
suggests	NULL
that	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
TRAIL	NULL
sensitivity	NULL
or	NULL
resistance	NULL
may	NULL
be	NULL
highly	NULL
complex	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
the	NULL
5	NULL
TRAIL-resistant	NULL
MM	NULL
cell	NULL
lines	NULL
(	NULL
ARH-77	NULL
,	NULL
IM-9	NULL
,	NULL
HS	NULL
Sultan	NULL
,	NULL
MM-AS	NULL
,	NULL
and	NULL
MM-SV	NULL
cells	NULL
)	NULL
in	NULL
our	NULL
study	NULL
may	NULL
represent	NULL
earlier	NULL
plasmacytes	NULL
or	NULL
late-stage	NULL
B	NULL
cells	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
their	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
CD20	NULL
,	NULL
which	NULL
is	NULL
lost	NULL
at	NULL
late	NULL
stages	NULL
of	NULL
plasmacytic	NULL
differentiation	NULL
.	NULL
``	NULL

These	NULL
findings	NULL
,	NULL
along	NULL
with	NULL
our	NULL
data	NULL
that	NULL
normal	NULL
B	NULL
cells	NULL
are	NULL
resistant	NULL
to	NULL
TRAIL/ApoZL	NULL
,	NULL
suggest	NULL
that	NULL
TRAIL	NULL
sensitivity	NULL
may	NULL
be	NULL
acquired	NULL
with	NULL
late	NULL
plasmacytic	NULL
differen-tiation	NULL
.	NULL

Changes	NULL
in	NULL
the	NULL
pattern	NULL
of	NULL
sensitivity	NULL
of	NULL
B-lineage	NULL
cells	NULL
to	NULL
TRAIL	NULL
during	NULL
differentiation	NULL
are	NULL
currently	NULL
under	NULL
evaluation	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

The	NULL
potent	NULL
and	NULL
selective	NULL
proapoptotic	NULL
effect	NULL
of	NULL
TRAIL/ApoZL	NULL
against	NULL
MM	NULL
patient	NULL
cells	NULL
and	NULL
most	NULL
MM	NULL
cell	NULL
lines	NULL
in	NULL
vitro	NULL
prompted	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
us	NULL
to	NULL
evaluate	NULL
its	NULL
in	NULL
vivo	NULL
anti-MM	NULL
effect	NULL
in	NULL
nu/bg/xid	NULL
mice	NULL
bearing	NULL
established	NULL
human	NULL
plasmacytoma	NULL
xenografts	NULL
.	NULL

Importantly	NULL
,	NULL
TRAIL	NULL
inhibited	NULL
the	NULL
growth	NULL
of	NULL
human	NULL
plasmacytomas	NULL
and	NULL
induced	NULL
complete	NULL
tumor	NULL
eradication	NULL
in	NULL
1	NULL
of	NULL
8	NULL
TRAIL-treated	NULL
animals	NULL
at	NULL
the	NULL
dose	NULL
regimen	NULL
(	NULL
ie	NULL
,	NULL
500	NULL
pug	NULL
daily	NULL
for	NULL
14	NULL
days	NULL
)	NULL
evaluated	NULL
.	NULL

Following	NULL
discontinuation	NULL
of	NULL
TRAIL	NULL
,	NULL
increases	NULL
in	NULL
the	NULL
mean	NULL
tumor	NULL
volumes	NULL
were	NULL
observed	NULL
in	NULL
TRAIL-treated	NULL
mice	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
selection	NULL
of	NULL
TRAIL-resistant	NULL
MM	NULL
cells	NULL
contributed	NULL
to	NULL
these	NULL
findings	NULL
because	NULL
plasmacytoma	NULL
cells	NULL
taken	NULL
from	NULL
2	NULL
mice	NULL
remained	NULL
sensitive	NULL
to	NULL
TRAIL	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
use	NULL
of	NULL
higher	NULL
TRAIL/	NULL
Apo2L	NULL
doses	NULL
may	NULL
be	NULL
more	NULL
effective	NULL
in	NULL
further	NULL
shrinking	NULL
or	NULL
eradicating	NULL
established	NULL
plasmacytomas	NULL
;	NULL
studies	NULL
evaluating	NULL
higher	NULL
doses	NULL
of	NULL
TRAIL/Apo2L	NULL
,	NULL
which	NULL
have	NULL
been	NULL
successfully	NULL
used	NULL
in	NULL
in	NULL
vivo	NULL
models	NULL
of	NULL
other	NULL
neoplasias	NULL
,	NULL
*	NULL
``	NULL
are	NULL
currently	NULL
under	NULL
way	NULL
in	NULL
our	NULL
MM	NULL
murine	NULL
model	NULL
.	NULL

Importantly	NULL
,	NULL
TRAIL/ApoZL	NULL
appeared	NULL
to	NULL
be	NULL
well	NULL
tolerated	NULL
by	NULL
the	NULL
mice	NULL
.	NULL

The	NULL
observed	NULL
responses	NULL
and	NULL
lack	NULL
of	NULL
toxicity	NULL
of	NULL
LZ-TRAIL	NULL
in	NULL
this	NULL
human	NULL
plasmacytoma	NULL
model	NULL
are	NULL
not	NULL
attributable	NULL
solely	NULL
to	NULL
differences	NULL
in	NULL
cross-species	NULL
activity	NULL
of	NULL
human	NULL
LZ-TRAIL	NULL
,	NULL
because	NULL
both	NULL
human	NULL
and	NULL
murine	NULL
TRAIL	NULL
are	NULL
equipotent	NULL
against	NULL
murine	NULL
cell	NULL
lines	NULL
in	NULL
vitro	NULL
.	NULL
``	NULL

However	NULL
,	NULL
recent	NULL
reports	NULL
of	NULL
potential	NULL
toxicity	NULL
of	NULL
the	NULL
LZ-TRAIL	NULL
to	NULL
human	NULL
hepatocytes	NULL
``	NULL
and	NULL
neuronal	NULL
tissues	NULL
``	NULL
suggest	NULL
that	NULL
other	NULL
forms	NULL
of	NULL
TRAIL	NULL
,	NULL
without	NULL
these	NULL
adverse	NULL
effects	NULL
,	NULL
may	NULL
be	NULL
preferable	NULL
for	NULL
future	NULL
clinical	NULL
use	NULL
.	NULL

Concerns	NULL
regarding	NULL
emergence	NULL
of	NULL
TRAIL	NULL
resistance	NULL
,	NULL
as	NULL
well	NULL
as	NULL
potential	NULL
TRAIL-related	NULL
side	NULL
effects	NULL
in	NULL
vivo	NULL
,	NULL
prompted	NULL
us	NULL
to	NULL
investigate	NULL
mechanisms	NULL
to	NULL
enhance	NULL
the	NULL
tumoricidal	NULL
activity	NULL
and	NULL
therapeutic	NULL
index	NULL
of	NULL
TRAIL/Apo2L-based	NULL
therapies	NULL
.	NULL

We	NULL
therefore	NULL
examined	NULL
whether	NULL
Dox	NULL
,	NULL
which	NULL
up-regulates	NULL
the	NULL
DR5	NULL
death	NULL
signaling	NULL
receptor**°	NULL
and	NULL
is	NULL
commonly	NULL
used	NULL
to	NULL
treat	NULL
MM	NULL
,	NULL
could	NULL
sensitize	NULL
MM	NULL
cells	NULL
to	NULL
TRAIL	NULL
.	NULL

We	NULL
demonstrated	NULL
that	NULL
pretreatment	NULL
of	NULL
several	NULL
MM	NULL
cell	NULL
lines	NULL
with	NULL
Dox	NULL
,	NULL
at	NULL
clinically	NULL
relevant	NULL
concentrations	NULL
,	NULL
significantly	NULL
enhanced	NULL
the	NULL
TRAIL	NULL
sensitivity	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

Specifically	NULL
,	NULL
Dox	NULL
induced	NULL
significant	NULL
up-regulation	NULL
of	NULL
the	NULL
DR5	NULL
receptor	NULL
expression	NULL
(	NULL
and	NULL
a	NULL
much	NULL
lesser	NULL
increase	NULL
in	NULL
DcR1	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
small	NULL
decrease	NULL
in	NULL
DcR2	NULL
expression	NULL
)	NULL
and	NULL
,	NULL
importantly	NULL
,	NULL
had	NULL
a	NULL
synergistic	NULL
interaction	NULL
with	NULL
TRAIL/ApoZL	NULL
in	NULL
inducing	NULL
apoptosis	NULL
of	NULL
MM-1S	NULL
cells	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
in	NULL
other	NULL
malignancies	NULL
.	NULL
``	NULL

We	NULL
showed	NULL
that	NULL
,	NULL
within	NULL
our	NULL
panel	NULL
of	NULL
MM	NULL
cell	NULL
lines	NULL
,	NULL
the	NULL
status	NULL
of	NULL
functional	NULL
or	NULL
``	NULL
decoy	NULL
``	NULL
TRAIL	NULL
receptors	NULL
at	NULL
baseline	NULL
can	NULL
not	NULL
per	NULL
se	NULL
explain	NULL
why	NULL
a	NULL
particular	NULL
cell	NULL
line	NULL
is	NULL
TRAIL	NULL
sensitive	NULL
or	NULL
resistant	NULL
(	NULL
possibly	NULL
due	NULL
to	NULL
downstream	NULL
intracellular	NULL
modulators	NULL
of	NULL
apoptosis	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
does	NULL
not	NULL
preclude	NULL
the	NULL
possibility	NULL
that	NULL
changes	NULL
of	NULL
surface	NULL
expression	NULL
of	NULL
TRAIL	NULL
receptor	NULL
(	NULL
s	NULL
)	NULL
in	NULL
each	NULL
particular	NULL
cell	NULL
line	NULL
(	NULL
eg	NULL
,	NULL
in	NULL
the	NULL
setting	NULL
of	NULL
Dox	NULL
stimulation	NULL
)	NULL
may	NULL
modulate	NULL
its	NULL
TRAIL	NULL
sensitivity	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
synergy	NULL
of	NULL
Dox	NULL
with	NULL
TRAIL	NULL
was	NULL
also	NULL
documented	NULL
against	NULL
MM	NULL
cells	NULL
resistant	NULL
to	NULL
Dex-	NULL
or	NULL
Dox-induced	NULL
apoptosis	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
molecular	NULL
pathway	NULL
(	NULL
s	NULL
)	NULL
underlying	NULL
this	NULL
synergy	NULL
are	NULL
independent	NULL
of	NULL
classical	NULL
mechanisms	NULL
of	NULL
drug	NULL
resistance	NULL
in	NULL
MM	NULL
cells	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
the	NULL
Dox-induced	NULL
sensitization	NULL
of	NULL
``	NULL
Dox-resistant	NULL
``	NULL
MM	NULL
cells	NULL
to	NULL
TRAIL/	NULL
Apo2L	NULL
suggests	NULL
that	NULL
Dox-induced	NULL
apoptosis	NULL
and	NULL
sensitization	NULL
to	NULL
TRAIL/Apo2L	NULL
constitute	NULL
distinct	NULL
biologic	NULL
end	NULL
points	NULL
and	NULL
are	NULL
likely	NULL
References	NULL
TRAIL/Apo2L-INDUCED	NULL
APOPTOSIS	NULL
OF	NULL
MULTIPLE	NULL
MYELOMA	NULL
CELLS	NULL
_	NULL
803	NULL
mediated	NULL
by	NULL
distinct	NULL
mechanisms	NULL
;	NULL
therefore	NULL
,	NULL
intracellular	NULL
Dox	NULL
concentrations	NULL
that	NULL
can	NULL
not	NULL
themselves	NULL
induce	NULL
apoptosis	NULL
may	NULL
be	NULL
sufficient	NULL
to	NULL
sensitize	NULL
MM	NULL
cells	NULL
to	NULL
TRAIL/Apo2L	NULL
.	NULL

Ongoing	NULL
efforts	NULL
are	NULL
delineating	NULL
the	NULL
mechanism	NULL
underlying	NULL
TRAIL/Apo2L	NULL
sensitization	NULL
and	NULL
DR5	NULL
up-regulation	NULL
by	NULL
Dox	NULL
.	NULL

We	NULL
also	NULL
investigated	NULL
whether	NULL
agents	NULL
that	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
could	NULL
also	NULL
sensitize	NULL
MM	NULL
cells	NULL
to	NULL
TRAIL/ApoZL	NULL
.	NULL

is	NULL
a	NULL
multifunc-tional	NULL
transcription	NULL
factor	NULL
that	NULL
serves	NULL
as	NULL
a	NULL
nodal	NULL
point	NULL
for	NULL
multiple	NULL
converging	NULL
signal	NULL
transduction	NULL
pathways	NULL
,	NULL
``	NULL
which	NULL
include	NULL
both	NULL
antiapoptotic	NULL
and	NULL
proapoptotic	NULL
stimuli	NULL
.	NULL

TRAIL/ApoZL	NULL
binding	NULL
to	NULL
DR4	NULL
and	NULL
DR5	NULL
,	NULL
as	NULL
well	NULL
as	NULL
to	NULL
decoy	NULL
receptor	NULL
DcR2	NULL
,	NULL
activates	NULL
by	NULL
RIP-mediated	NULL
activation	NULL
of	NULL
IxB	NULL
kinase	NULL
.	NULL
``	NULL

NF-KB	NULL
is	NULL
an	NULL
important	NULL
constituent	NULL
of	NULL
cell	NULL
survival	NULL
pathways	NULL
for	NULL
MM	NULL
!	NULL

and	NULL
other	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
and	NULL
confers	NULL
protection	NULL
of	NULL
tumor	NULL
cells	NULL
against	NULL
various	NULL
proapoptotic	NULL
stimuli	NULL
.	NULL

Conversely	NULL
,	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
by	NULL
transfec-tion	NULL
with	NULL
superrepressor	NULL
forms	NULL
of	NULL
IB	NULL
sensitized	NULL
chemoresistant	NULL
fibrosarcoma	NULL
cells	NULL
to	NULL
TNF-	NULL
«	NULL
and	NULL
the	NULL
topoisomerase	NULL
I	NULL
inhibitor	NULL
CPT-11.5°	NULL
We	NULL
therefore	NULL
examined	NULL
whether	NULL
2	NULL
agents	NULL
that	NULL
inhibit	NULL
NE-	NULL
«	NULL
B	NULL
activity	NULL
(	NULL
SN50	NULL
and	NULL
PS-341	NULL
)	NULL
could	NULL
sensitize	NULL
MM	NULL
cells	NULL
to	NULL
TRAIL/Apo2L-induced	NULL
apoptosis	NULL
.	NULL

In	NULL
several	NULL
TRAIL-sensitive	NULL
MM	NULL
cells	NULL
,	NULL
pretreatment	NULL
with	NULL
SN50	NULL
markedly	NULL
enhanced	NULL
sensitivity	NULL
to	NULL
TRAIL	NULL
.	NULL

Moreover	NULL
,	NULL
pretreatment	NULL
with	NULL
SN50	NULL
reversed	NULL
the	NULL
TRAIL-resistant	NULL
phenotype	NULL
of	NULL
ARH-77	NULL
and	NULL
IM-9	NULL
MM	NULL
cells	NULL
.	NULL

Pretreatment	NULL
of	NULL
MM-18	NULL
cells	NULL
with	NULL
PS-341	NULL
,	NULL
which	NULL
also	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
activa-tion	NULL
,	NULL
enhanced	NULL
the	NULL
sensitivity	NULL
to	NULL
TRAIL	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
NE-	NULL
«	NULL
B	NULL
activity	NULL
may	NULL
be	NULL
a	NULL
major	NULL
determinant	NULL
of	NULL
responsiveness	NULL
to	NULL
TRAIL/Apo2L	NULL
in	NULL
MM	NULL
and	NULL
an	NULL
attractive	NULL
target	NULL
for	NULL
therapeutic	NULL
strategies	NULL
to	NULL
augment	NULL
TRAIL/ApoZL	NULL
efficacy	NULL
or	NULL
reverse	NULL
TRAIL	NULL
resistance	NULL
in	NULL
MM	NULL
cells	NULL
.	NULL

In	NULL
anticipation	NULL
of	NULL
future	NULL
clinical	NULL
trials	NULL
of	NULL
TRAIL/ApoZL	NULL
alone	NULL
and	NULL
in	NULL
combination	NULL
with	NULL
TRAIL/Apo2L-sensitizing	NULL
agents	NULL
,	NULL
we	NULL
determined	NULL
whether	NULL
TRAIL-resistant	NULL
normal	NULL
hematopoietic	NULL
cells	NULL
are	NULL
also	NULL
sensitized	NULL
to	NULL
TRAIL/ApoZL	NULL
by	NULL
pretreatment	NULL
with	NULL
Dox	NULL
or	NULL
NE-	NULL
«	NULL
B	NULL
inhibition	NULL
.	NULL

Importantly	NULL
,	NULL
pretreatement	NULL
with	NULL
Dox	NULL
,	NULL
SN50	NULL
,	NULL
or	NULL
PS-341	NULL
(	NULL
under	NULL
the	NULL
same	NULL
experimental	NULL
conditions	NULL
that	NULL
sensitized	NULL
MM	NULL
cells	NULL
to	NULL
TRAIL/Apo2L	NULL
)	NULL
did	NULL
not	NULL
sensitize	NULL
normal	NULL
peripheral	NULL
blood	NULL
B	NULL
cells	NULL
to	NULL
TRAIL/Apo2L	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
the	NULL
potential	NULL
utility	NULL
of	NULL
TRAIL-based	NULL
combination	NULL
therapies	NULL
to	NULL
selectively	NULL
target	NULL
MM	NULL
cells	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
TRAIL/Apo2L	NULL
is	NULL
a	NULL
potent	NULL
and	NULL
selective	NULL
inducer	NULL
of	NULL
apoptosis	NULL
in	NULL
drug-sensitive	NULL
and	NULL
drug-resistant	NULL
MM	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
patient	NULL
MM	NULL
cells	NULL
.	NULL

TRAIL/Apo2L-induced	NULL
apoptosis	NULL
of	NULL
MM	NULL
cells	NULL
is	NULL
not	NULL
abrogated	NULL
by	NULL
IL-6	NULL
,	NULL
a	NULL
major	NULL
growth	NULL
and	NULL
survival	NULL
factor	NULL
for	NULL
MM	NULL
cells	NULL
.	NULL

Factors	NULL
other	NULL
than	NULL
TRAIL	NULL
receptor	NULL
status	NULL
likely	NULL
account	NULL
for	NULL
patterns	NULL
of	NULL
TRAIL	NULL
sensitivity	NULL
and	NULL
resistance	NULL
in	NULL
MM	NULL
cells	NULL
and	NULL
are	NULL
currently	NULL
being	NULL
evaluated	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

TRAIL	NULL
exhibited	NULL
anti-MM	NULL
activity	NULL
in	NULL
vivo	NULL
in	NULL
mice	NULL
xenografted	NULL
with	NULL
human	NULL
plasmacytomas	NULL
.	NULL

Lastly	NULL
,	NULL
Dox	NULL
and	NULL
agents	NULL
inhibiting	NULL
NE-	NULL
«	NULL
B	NULL
sensitized	NULL
MM	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
normal	NULL
B	NULL
cells	NULL
,	NULL
to	NULL
TRAIL/	NULL
Apo2L-induced	NULL
apoptosis	NULL
.	NULL

These	NULL
studies	NULL
therefore	NULL
provide	NULL
a	NULL
framework	NULL
for	NULL
clinical	NULL
trials	NULL
examining	NULL
the	NULL
use	NULL
of	NULL
single-agent	NULL
and	NULL
combined	NULL
TRAIL/Apo2L-based	NULL
therapies	NULL
in	NULL
MM	NULL
.	NULL

1	NULL
.	NULL

Aftal	NULL
M	NULL
,	NULL
Harousseau	NULL
JL	NULL
,	NULL
Stoppa	NULL
AM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

A	NULL
pro-spective	NULL
,	NULL
randomized	NULL
trial	NULL
of	NULL
autologous	NULL
bone	NULL
marrow	NULL
transplantation	NULL
and	NULL
chemotherapy	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
.	NULL

1996	NULL
;	NULL
335:91-97	NULL
.	NULL

Bataille	NULL
R	NULL
,	NULL
Harousseau	NULL
JL	NULL
.	NULL

Multiple	NULL
myeloma	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
.	NULL

1997	NULL
;	NULL
336:1657-1664	NULL
.	NULL

3	NULL
.	NULL

Schlossman	NULL
RL	NULL
,	NULL
Anderson	NULL
KC	NULL
.	NULL

Bone	NULL
marrow	NULL
transplantation	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

Curr	NULL
Opin	NULL
Oncol	NULL
.	NULL

1999	NULL
;	NULL
11:102-108	NULL
.	NULL

163	NULL
.	NULL

6	NULL
.	NULL

4	NULL
.	NULL

Walczak	NULL
H	NULL
,	NULL
Miller	NULL
RE	NULL
,	NULL
Ariail	NULL
K	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Turnoricidal	NULL
activity	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor-related	NULL
apoptosis-inducing	NULL
ligand	NULL
in	NULL
vivo	NULL
.	NULL

Nat	NULL
Med	NULL
.	NULL

1999	NULL
;	NULL
5:157-	NULL
.	NULL

Schulze-Osthoff	NULL
K	NULL
,	NULL
Ferrari	NULL
D	NULL
,	NULL
Los	NULL
M	NULL
,	NULL
Wesselborg	NULL
S	NULL
,	NULL
Peter	NULL
ME	NULL
.	NULL

Apoptosis	NULL
signaling	NULL
by	NULL
death	NULL
recep-tors	NULL
.	NULL

Eur	NULL
J	NULL
Biochem	NULL
.	NULL

1998	NULL
;	NULL
254:439-459	NULL
.	NULL

Griffith	NULL
TS	NULL
,	NULL
Chin	NULL
WA	NULL
,	NULL
Jackson	NULL
GC	NULL
,	NULL
Lynch	NULL
DH	NULL
,	NULL
Kubin	NULL
MZ	NULL
.	NULL

Intracellular	NULL
regulation	NULL
of	NULL
TRAIL-in-	NULL
duced	NULL
apoptosis	NULL
in	NULL
human	NULL
melanoma	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
161:2833-2840	NULL
.	NULL

Ashkenazi	NULL
A	NULL
,	NULL
Pai	NULL
RC	NULL
,	NULL
Fong	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Safety	NULL
and	NULL
antitumor	NULL
activity	NULL
of	NULL
recombinant	NULL
soluble	NULL
Apo2	NULL
ligand	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1999	NULL
;	NULL
104:155-162	NULL
.	NULL

8	NULL
.	NULL

Pitti	NULL
RM	NULL
,	NULL
Marsters	NULL
SA	NULL
,	NULL
Ruppert	NULL
S	NULL
,	NULL
Donahue	NULL
CJ	NULL
,	NULL
Moore	NULL
A	NULL
,	NULL
Ashkenazi	NULL
A	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
by	NULL
Apo-2	NULL
ligand	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
turnor	NULL
necrosis	NULL
factor	NULL
cytokine	NULL
family	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

1996	NULL
;	NULL
271	NULL
:	NULL
12687-12690	NULL
.	NULL

7	NULL
.	NULL

804	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

MITSIADES	NULL
et	NULL
al	NULL
Rieger	NULL
J	NULL
,	NULL
Naumann	NULL
U	NULL
,	NULL
Glaser	NULL
T	NULL
,	NULL
Ashkenazi	NULL
A	NULL
,	NULL
Weller	NULL
M.	NULL
APO2	NULL
ligand	NULL
:	NULL
a	NULL
novel	NULL
lethal	NULL
weapon	NULL
against	NULL
malignant	NULL
glioma	NULL
?	NULL

FEBS	NULL
Lett	NULL
.	NULL

1998	NULL
;	NULL
427	NULL
:	NULL
124-128	NULL
.	NULL

Wiley	NULL
SR	NULL
,	NULL
Schooley	NULL
K	NULL
,	NULL
Smolak	NULL
PJ	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
TNF	NULL
family	NULL
that	NULL
induces	NULL
apoptosis	NULL
.	NULL

Immunity	NULL
.	NULL

1995	NULL
;	NULL
3:673-682	NULL
.	NULL

Thomas	NULL
WD	NULL
,	NULL
Hersey	NULL
P.	NULL
TNF-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
induces	NULL
apoptosis	NULL
in	NULL
Fas	NULL
ligand-resistant	NULL
melanoma	NULL
cells	NULL
and	NULL
mediates	NULL
CD4	NULL
T	NULL
cell	NULL
killing	NULL
of	NULL
target	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
161:2195-2200	NULL
.	NULL

Mori	NULL
S	NULL
,	NULL
Murakami-Mori	NULL
K	NULL
,	NULL
Nakamura	NULL
S	NULL
,	NULL
Ashkenazi	NULL
A	NULL
,	NULL
Bonavida	NULL
B.	NULL
Sensitization	NULL
of	NULL
AIDS-Kaposi	NULL
's	NULL
sarcoma	NULL
cells	NULL
to	NULL
Apo-2	NULL
ligand-induced	NULL
apoptosis	NULL
by	NULL
actinomycin	NULL
D.	NULL
J	NULL
Immunol	NULL
.	NULL

1999	NULL
;	NULL
162:5616-5623	NULL
.	NULL

Yu	NULL
R	NULL
,	NULL
Mandlekar	NULL
S	NULL
,	NULL
Ruben	NULL
S	NULL
,	NULL
Ni	NULL
J	NULL
,	NULL
Kong	NULL
AN	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor-related	NULL
apoptosis-inducing	NULL
ligand-mediated	NULL
apoptosis	NULL
in	NULL
androgen-indepen-dent	NULL
prostate	NULL
cancer	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

2000	NULL
;	NULL
60	NULL
:	NULL
2384-2389	NULL
.	NULL

Mitsiades	NULL
N	NULL
,	NULL
Poulaki	NULL
V	NULL
,	NULL
Tseleni-Balafouta	NULL
S	NULL
,	NULL
Koutras	NULL
DA	NULL
,	NULL
Stamenkovie	NULL
I.	NULL
Thyroid	NULL
carcinoma	NULL
cells	NULL
are	NULL
resistant	NULL
to	NULL
FAS-mediated	NULL
apoptosis	NULL
but	NULL
sensitive	NULL
to	NULL
tunor	NULL
necrosis	NULL
factor-related	NULL
apoptosis-inducing	NULL
ligand	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

2000	NULL
;	NULL
60:4122-4129	NULL
.	NULL

Mitsiades	NULL
N	NULL
,	NULL
Poulaki	NULL
V	NULL
,	NULL
Mitsiades	NULL
C	NULL
,	NULL
Tsokos	NULL
M.	NULL
Ewing	NULL
's	NULL
sarcoma	NULL
family	NULL
tumors	NULL
are	NULL
sensitive	NULL
to	NULL
tumor	NULL
necrosis	NULL
factor-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
and	NULL
express	NULL
DR4	NULL
and	NULL
DRS	NULL
recep-tors	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

2001	NULL
;	NULL
618:2704-2712	NULL
.	NULL

Griffith	NULL
TS	NULL
,	NULL
Lynch	NULL
DH	NULL
.	NULL

TRAIL	NULL
:	NULL
a	NULL
molecule	NULL
with	NULL
multiple	NULL
receptors	NULL
and	NULL
control	NULL
mechanisms	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
10:559-563	NULL
.	NULL

Treon	NULL
SP	NULL
,	NULL
Chauhan	NULL
D	NULL
,	NULL
Raje	NULL
N	NULL
,	NULL
Teoh	NULL
G	NULL
,	NULL
Webb	NULL
I	NULL
,	NULL
Anderson	NULL
KC	NULL
.	NULL

Recombinant	NULL
human	NULL
TNF-related	NULL
apoptosis	NULL
inducing	NULL
ligand	NULL
(	NULL
hu	NULL
TRAIL	NULL
)	NULL
induces	NULL
apoptosis	NULL
of	NULL
human	NULL
multiple	NULL
myeloma	NULL
(	NULL
MM	NULL
)	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

1998	NULL
;	NULL
92:634a	NULL
.	NULL

Treon	NULL
SP	NULL
,	NULL
Mitsiades	NULL
CS	NULL
,	NULL
Mitsiades	NULL
NS	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Tumor	NULL
cell	NULL
expression	NULL
of	NULL
CD59	NULL
may	NULL
contribute	NULL
to	NULL
rituximab	NULL
resistance	NULL
in	NULL
B-cell	NULL
malignancies	NULL
.	NULL

2000	NULL
.	NULL

In	NULL
press	NULL
.	NULL

Mitsiades	NULL
N	NULL
,	NULL
Poulaki	NULL
V	NULL
,	NULL
Kotoula	NULL
V	NULL
,	NULL
Leone	NULL
A	NULL
,	NULL
Tsokos	NULL
M.	NULL
Fas	NULL
ligand	NULL
is	NULL
present	NULL
in	NULL
tumors	NULL
of	NULL
the	NULL
Ewing	NULL
's	NULL
sarcoma	NULL
family	NULL
and	NULL
is	NULL
cleaved	NULL
into	NULL
a	NULL
soluble	NULL
form	NULL
by	NULL
a	NULL
metalloproteinase	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
.	NULL

1998	NULL
;	NULL
153:1947-1956	NULL
.	NULL

Treon	NULL
SP	NULL
,	NULL
Mollick	NULL
JA	NULL
,	NULL
Urashima	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Muc-1	NULL
core	NULL
protein	NULL
is	NULL
expressed	NULL
on	NULL
multiple	NULL
myeloma	NULL
cells	NULL
and	NULL
is	NULL
induced	NULL
by	NULL
dexamethasone	NULL
.	NULL

Blood	NULL
.	NULL

1999	NULL
;	NULL
93:1287-1298	NULL
.	NULL

Treon	NULL
SP	NULL
,	NULL
Maimonis	NULL
P	NULL
,	NULL
Bua	NULL
D	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Elevated	NULL
soluble	NULL
MUC1	NULL
levels	NULL
and	NULL
decreased	NULL
anti-MUC1	NULL
antibody	NULL
levels	NULL
in	NULL
patients	NULL
with	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
.	NULL

2000	NULL
;	NULL
96:3147-3153	NULL
.	NULL

Treon	NULL
SP	NULL
,	NULL
Teoh	NULL
G	NULL
,	NULL
Urashima	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Anti-estro-gens	NULL
induce	NULL
apoptosis	NULL
of	NULL
multiple	NULL
myeloma	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

1998	NULL
;	NULL
92:1749-1757	NULL
.	NULL

Zhang	NULL
C	NULL
,	NULL
Ao	NULL
Z	NULL
,	NULL
Seth	NULL
A	NULL
,	NULL
Schlossman	NULL
SF	NULL
.	NULL

A	NULL
mitochondrial	NULL
membrane	NULL
protein	NULL
defined	NULL
by	NULL
a	NULL
novel	NULL
monoclonal	NULL
antibody	NULL
is	NULL
preferentially	NULL
detected	NULL
in	NULL
apoptotic	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
157:3980-3987	NULL
.	NULL

Seth	NULL
A	NULL
,	NULL
Zhang	NULL
C	NULL
,	NULL
Letvin	NULL
NL	NULL
,	NULL
Schlossman	NULL
SF	NULL
.	NULL

Detection	NULL
of	NULL
apoptotic	NULL
cells	NULL
from	NULL
peripheral	NULL
blood	NULL
of	NULL
HIV-infected	NULL
individuals	NULL
using	NULL
a	NULL
novel	NULL
monoclonal	NULL
antibody	NULL
.	NULL

AIDS	NULL
.	NULL

1997	NULL
;	NULL
11:1059-1061	NULL
.	NULL

Hardin	NULL
J	NULL
,	NULL
MacLeod	NULL
S	NULL
,	NULL
Grigorieva	NULL
1	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Interleukin-6	NULL
prevents	NULL
dexamethasone-induced	NULL
myeloma	NULL
cell	NULL
death	NULL
.	NULL

Blood	NULL
.	NULL

1994	NULL
;	NULL
84:3063-3070	NULL
.	NULL

Chauhan	NULL
D	NULL
,	NULL
Pandey	NULL
P	NULL
,	NULL
Hideshima	NULL
T	NULL
,	NULL
et	NULL
al	NULL
.	NULL

SHP2	NULL
mediates	NULL
the	NULL
protective	NULL
effect	NULL
of	NULL
interleukin-6	NULL
27	NULL
.	NULL

286	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44.	NULL
against	NULL
dexamethasone-induced	NULL
apoptosis	NULL
in	NULL
multiple	NULL
myeloma	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

2000	NULL
;	NULL
275	NULL
:	NULL
27845-27850	NULL
.	NULL

Webb	NULL
JL	NULL
.	NULL

Enzymes	NULL
and	NULL
metabolic	NULL
inhibitors	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

1963	NULL
;	NULL
1:66-79	NULL
.	NULL

Chauhan	NULL
D	NULL
,	NULL
Kharbanda	NULL
S	NULL
,	NULL
Ogata	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Interleukin-6	NULL
inhibits	NULL
Fas-induced	NULL
apoptosis	NULL
and	NULL
stress-activated	NULL
protein	NULL
kinase	NULL
activation	NULL
in	NULL
multiple	NULL
myeloma	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

1997	NULL
;	NULL
89:227-234	NULL
.	NULL

Takahashi	NULL
T	NULL
,	NULL
Okuno	NULL
Y	NULL
,	NULL
Ohsugi	NULL
Y	NULL
.	NULL

Growth	NULL
characteristics	NULL
of	NULL
a	NULL
human	NULL
myeloma	NULL
cell	NULL
line	NULL
transfected	NULL
with	NULL
IL-6	NULL
cDNA	NULL
.	NULL

Rinsho	NULL
Ketsueki	NULL
.	NULL

1993	NULL
;	NULL
34:423-426	NULL
.	NULL

Keane	NULL
MM	NULL
,	NULL
Ettenberg	NULL
SA	NULL
,	NULL
Nau	NULL
MM	NULL
,	NULL
Russell	NULL
EK	NULL
,	NULL
Lipkowitz	NULL
S.	NULL
Chemotherapy	NULL
augments	NULL
TRAIL-induced	NULL
apoptosis	NULL
in	NULL
breast	NULL
cell	NULL
lines	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

1999	NULL
;	NULL
59:734-741	NULL
.	NULL

Feinman	NULL
R	NULL
,	NULL
Koury	NULL
J	NULL
,	NULL
Thames	NULL
M	NULL
,	NULL
Barlogie	NULL
B	NULL
,	NULL
Epstein	NULL
J	NULL
,	NULL
Siege	NULL
!	NULL

DS	NULL
.	NULL

Role	NULL
of	NULL
NF-kappa	NULL
B	NULL
in	NULL
the	NULL
rescue	NULL
of	NULL
multiple	NULL
myeloma	NULL
cells	NULL
from	NULL
glucocorti-coid-induced	NULL
apoptosis	NULL
by	NULL
bel-2	NULL
.	NULL

Blood	NULL
.	NULL

1999	NULL
;	NULL
93	NULL
:	NULL
3044-3052	NULL
.	NULL

Lin	NULL
YZ	NULL
,	NULL
Yao	NULL
SY	NULL
,	NULL
Veach	NULL
RA	NULL
,	NULL
Torgerson	NULL
TR	NULL
,	NULL
Ha-wiger	NULL
J.	NULL
Inhibition	NULL
of	NULL
nuclear	NULL
translocation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-kappa	NULL
B	NULL
by	NULL
a	NULL
synthetic	NULL
peptide	NULL
containing	NULL
a	NULL
cell	NULL
membrane-permeable	NULL
motif	NULL
and	NULL
nuclear	NULL
localization	NULL
sequence	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

1995	NULL
;	NULL
270:14255-14258	NULL
.	NULL

Palombella	NULL
VJ	NULL
,	NULL
Rando	NULL
OJ	NULL
,	NULL
Goldberg	NULL
AL	NULL
,	NULL
Maniatis	NULL
T.	NULL
The	NULL
ubiquitin-proteasome	NULL
pathway	NULL
is	NULL
required	NULL
for	NULL
processing	NULL
the	NULL
NF-kappa	NULL
B1	NULL
precursor	NULL
protein	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
NF-kappa	NULL
B	NULL
.	NULL

Cell	NULL
.	NULL

1994	NULL
;	NULL
78	NULL
:	NULL
773-785	NULL
.	NULL

Zhao	NULL
S	NULL
,	NULL
Asgary	NULL
Z	NULL
,	NULL
Wang	NULL
Y	NULL
,	NULL
Goodwin	NULL
R	NULL
,	NULL
Andreeff	NULL
M	NULL
,	NULL
Younes	NULL
A.	NULL
Functional	NULL
expression	NULL
of	NULL
TRAIL	NULL
by	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
tumour	NULL
cells	NULL
.	NULL

Br	NULL
J	NULL
Haema-tol	NULL
.	NULL

1999	NULL
;	NULL
106:827-832	NULL
.	NULL

Gazitt	NULL
Y	NULL
.	NULL

TRAIL	NULL
is	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
apoptosis	NULL
in	NULL
myeloma	NULL
cells	NULL
derived	NULL
from	NULL
multiple	NULL
myeloma	NULL
patients	NULL
and	NULL
is	NULL
not	NULL
cytotoxic	NULL
to	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
.	NULL

Leukemia	NULL
.	NULL

1999	NULL
;	NULL
13:1817-1824	NULL
.	NULL

Gazitt	NULL
Y	NULL
,	NULL
Shaughnessy	NULL
P	NULL
,	NULL
Montgomery	NULL
W.	NULL
Apo-ptosis-induced	NULL
by	NULL
TRAIL	NULL
and	NULL
TNF-alpha	NULL
in	NULL
human	NULL
multiple	NULL
myeloma	NULL
cells	NULL
is	NULL
not	NULL
blocked	NULL
by	NULL
BCL-2	NULL
.	NULL

Cytokine	NULL
.	NULL

1999	NULL
;	NULL
11:1010-1019	NULL
.	NULL

Bonavida	NULL
B	NULL
,	NULL
Ng	NULL
CP	NULL
,	NULL
Jazirehi	NULL
A	NULL
,	NULL
Schiller	NULL
G	NULL
,	NULL
Mizu-tani	NULL
Y.	NULL
Selectivity	NULL
of	NULL
TRAIL-mediated	NULL
apoptosis	NULL
of	NULL
cancer	NULL
cells	NULL
and	NULL
synergy	NULL
with	NULL
drugs	NULL
:	NULL
the	NULL
trail	NULL
to	NULL
non-toxic	NULL
cancer	NULL
therapeutics	NULL
[	NULL
review	NULL
]	NULL
.	NULL

Int	NULL
J	NULL
Oncol	NULL
.	NULL

1999	NULL
;	NULL
15:793-802	NULL
.	NULL

Treon	NULL
SP	NULL
,	NULL
Anderson	NULL
KC	NULL
.	NULL

Interleukin-6	NULL
in	NULL
multiple	NULL
myeloma	NULL
and	NULL
related	NULL
plasma	NULL
cell	NULL
dyscrasias	NULL
.	NULL

Curr	NULL
Opin	NULL
Hematol	NULL
.	NULL

1998	NULL
;	NULL
5:42-48	NULL
.	NULL

Pai	NULL
Sl	NULL
,	NULL
Wu	NULL
GS	NULL
,	NULL
Ozoren	NULL
N	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Rare	NULL
loss-of-function	NULL
mutation	NULL
of	NULL
a	NULL
death	NULL
receptor	NULL
gene	NULL
in	NULL
head	NULL
and	NULL
neck	NULL
cancer	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

1998	NULL
;	NULL
58	NULL
:	NULL
3513-3518	NULL
.	NULL

Lee	NULL
SH	NULL
,	NULL
Shin	NULL
MS	NULL
,	NULL
Kim	NULL
HS	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Alterations	NULL
of	NULL
the	NULL
DR5/TRAIL	NULL
receptor	NULL
2	NULL
gene	NULL
in	NULL
non-small	NULL
cell	NULL
lung	NULL
cancers	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

1999	NULL
;	NULL
59:5683-5686	NULL
.	NULL

Griffith	NULL
TS	NULL
,	NULL
Rauch	NULL
CT	NULL
,	NULL
Smolak	NULL
PJ	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
T	NULL
RAIL	NULL
receptors	NULL
using	NULL
monoclonal	NULL
antibodies	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1999	NULL
;	NULL
162:2597-2605	NULL
.	NULL

Zhang	NULL
XD	NULL
,	NULL
Franco	NULL
A	NULL
,	NULL
Myers	NULL
K	NULL
,	NULL
Gray	NULL
C	NULL
,	NULL
Nguyen	NULL
T	NULL
,	NULL
Hersey	NULL
P.	NULL
Relation	NULL
of	NULL
TNF-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
receptor	NULL
and	NULL
FLICE-inhibi-tory	NULL
protein	NULL
expression	NULL
to	NULL
TRAIL-induced	NULL
apoptosis	NULL
of	NULL
melanoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

1999	NULL
;	NULL
59:2747-2753	NULL
.	NULL

Kim	NULL
K	NULL
,	NULL
Fisher	NULL
MJ	NULL
,	NULL
Xu	NULL
SQ	NULL
,	NULL
el-Deiry	NULL
WS	NULL
.	NULL

Molecular	NULL
determinants	NULL
of	NULL
response	NULL
to	NULL
TRAIL	NULL
in	NULL
killing	NULL
of	NULL
normal	NULL
and	NULL
cancer	NULL
cells	NULL
.	NULL

Clin	NULL
Cancer	NULL
Res	NULL
.	NULL

2000	NULL
;	NULL
6:335-346	NULL
.	NULL

Zhang	NULL
XD	NULL
,	NULL
Franco	NULL
AV	NULL
,	NULL
Nguyen	NULL
T	NULL
,	NULL
Gray	NULL
CP	NULL
,	NULL
Hersey	NULL
P.	NULL
Differential	NULL
localization	NULL
and	NULL
regulation	NULL
of	NULL
45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
death	NULL
and	NULL
decoy	NULL
receptors	NULL
for	NULL
TNF-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
in	NULL
human	NULL
melanoma	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

2000	NULL
;	NULL
164:3961-3970	NULL
.	NULL

Himmelmann	NULL
A	NULL
,	NULL
Riva	NULL
A	NULL
,	NULL
Wilson	NULL
GL	NULL
,	NULL
Lucas	NULL
BP	NULL
,	NULL
Thevenin	NULL
C	NULL
,	NULL
Kehrl	NULL
JH	NULL
.	NULL

PU.1/Pip	NULL
and	NULL
basic	NULL
helix	NULL
loop	NULL
helix	NULL
zipper	NULL
transcription	NULL
factors	NULL
interact	NULL
with	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
to	NULL
help	NULL
confer	NULL
lineage-	NULL
and	NULL
stage-specific	NULL
expression	NULL
of	NULL
CD20	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

Blood	NULL
.	NULL

1997	NULL
;	NULL
90:3984-3995	NULL
.	NULL

Jo	NULL
M	NULL
,	NULL
Kim	NULL
TH	NULL
,	NULL
Seo	NULL
!	NULL

DW	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Apoptosis	NULL
induced	NULL
in	NULL
normal	NULL
human	NULL
hepatocytes	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor-related	NULL
apoptosis-inducing	NULL
ligand	NULL
.	NULL

Nat	NULL
Med	NULL
.	NULL

2000	NULL
;	NULL
6:564-567	NULL
.	NULL

Nitsch	NULL
R	NULL
,	NULL
Bechmann	NULL
I	NULL
,	NULL
Deisz	NULL
RA	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Human	NULL
brain-cell	NULL
death	NULL
induced	NULL
by	NULL
tumour-necrosis-fac-tor-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
[	NULL
let-ter	NULL
]	NULL
.	NULL

Lancet	NULL
.	NULL

2000	NULL
;	NULL
356:827-828	NULL
.	NULL

Wu	NULL
GS	NULL
,	NULL
Burns	NULL
TF	NULL
,	NULL
McDonald	NULL
ERI	NULL
,	NULL
et	NULL
al	NULL
.	NULL

KILLER/	NULL
DRS	NULL
is	NULL
a	NULL
DNA	NULL
damage-inducible	NULL
p53-regulated	NULL
receptor	NULL
gene	NULL
.	NULL

Nat	NULL
Genet	NULL
.	NULL

1997	NULL
;	NULL
17:141-143	NULL
.	NULL

Sheikh	NULL
MS	NULL
,	NULL
Burns	NULL
TF	NULL
,	NULL
Huang	NULL
Y	NULL
,	NULL
et	NULL
al	NULL
.	NULL

p53-depen-dent	NULL
and	NULL
-independent	NULL
regulation	NULL
of	NULL
the	NULL
death	NULL
receptor	NULL
KILLER/DRS	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
genotoxic	NULL
stress	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

1998	NULL
;	NULL
58:1593-1598	NULL
.	NULL

Nagane	NULL
M	NULL
,	NULL
Pan	NULL
G	NULL
,	NULL
Weddle	NULL
JJ	NULL
,	NULL
Dixit	NULL
VM	NULL
,	NULL
Cavenee	NULL
WK	NULL
,	NULL
Huang	NULL
HJ	NULL
.	NULL

Increased	NULL
death	NULL
receptor	NULL
5	NULL
expression	NULL
by	NULL
chemotherapeutic	NULL
agents	NULL
in	NULL
human	NULL
gliomas	NULL
causes	NULL
synergistic	NULL
cytotoxicity	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor-related	NULL
apoptosis-inducing	NULL
ligand	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

2000	NULL
;	NULL
60:847-853	NULL
.	NULL

Gibson	NULL
SB	NULL
,	NULL
Oyer	NULL
R	NULL
,	NULL
Spalding	NULL
AC	NULL
,	NULL
Anderson	NULL
SM	NULL
,	NULL
Johnson	NULL
GL	NULL
.	NULL

Increased	NULL
expression	NULL
of	NULL
death	NULL
receptors	NULL
4	NULL
and	NULL
5	NULL
synergizes	NULL
the	NULL
apoptosis	NULL
response	NULL
to	NULL
combined	NULL
treatment	NULL
with	NULL
etoposide	NULL
and	NULL
TRAIL	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

2000	NULL
;	NULL
20:205-212	NULL
.	NULL

Mercurio	NULL
F	NULL
,	NULL
Manning	NULL
AM	NULL
.	NULL

Multiple	NULL
signals	NULL
converging	NULL
on	NULL
NF-kappa	NULL
B.	NULL
Curr	NULL
Opin	NULL
Cell	NULL
Biol	NULL
.	NULL

1999	NULL
;	NULL
11:226-232	NULL
.	NULL

Chaudhary	NULL
PM	NULL
,	NULL
Eby	NULL
M	NULL
,	NULL
Jasmin	NULL
A	NULL
,	NULL
Bookwalter	NULL
A	NULL
,	NULL
Murray	NULL
J	NULL
,	NULL
Hood	NULL
L.	NULL
Death	NULL
receptor	NULL
5	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
TNFR	NULL
family	NULL
,	NULL
and	NULL
DR4	NULL
induce	NULL
FADD-dependent	NULL
apoptosis	NULL
and	NULL
activate	NULL
the	NULL
NF-kappa	NULL
B	NULL
pathway	NULL
.	NULL

Immunity	NULL
.	NULL

1997	NULL
;	NULL
7:821-830	NULL
.	NULL

Degli-Esposti	NULL
MA	NULL
,	NULL
Dougall	NULL
WC	NULL
,	NULL
Smolak	NULL
PJ	NULL
,	NULL
Waugh	NULL
JY	NULL
,	NULL
Smith	NULL
CA	NULL
,	NULL
Goodwin	NULL
RG	NULL
.	NULL

The	NULL
novel	NULL
receptor	NULL
TRAIL-R4	NULL
induces	NULL
NF-kappa	NULL
B	NULL
and	NULL
protects	NULL
against	NULL
TRAIL-mediated	NULL
apoptosis	NULL
,	NULL
yet	NULL
retains	NULL
an	NULL
incomplete	NULL
death	NULL
domain	NULL
.	NULL

Immunity	NULL
.	NULL

1997	NULL
;	NULL
7:813-820	NULL
.	NULL

Muhlenbeck	NULL
F	NULL
,	NULL
Haas	NULL
E	NULL
,	NULL
Schwenzer	NULL
R	NULL
,	NULL
et	NULL
al	NULL
.	NULL

TRAIL/Apo2L	NULL
activates	NULL
c-Jun	NULL
NH2-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
via	NULL
caspase-dependent	NULL
and	NULL
caspase-independent	NULL
pathways	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

1998	NULL
;	NULL
273	NULL
:	NULL
33091-33098	NULL
.	NULL

Schneider	NULL
P	NULL
,	NULL
Thome	NULL
M	NULL
,	NULL
Burns	NULL
K	NULL
,	NULL
et	NULL
al	NULL
.	NULL

TRAIL	NULL
receptors	NULL
1	NULL
(	NULL
DR4	NULL
)	NULL
and	NULL
2	NULL
(	NULL
DRS	NULL
)	NULL
signal	NULL
FADD-depen-dent	NULL
apoptosis	NULL
and	NULL
activate	NULL
NF-kappa	NULL
B	NULL
.	NULL

Immunity	NULL
.	NULL

1997	NULL
;	NULL
7:831-836	NULL
.	NULL

Lin	NULL
Y	NULL
,	NULL
Devin	NULL
A	NULL
,	NULL
Cook	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
death	NULL
domain	NULL
kinase	NULL
RIP	NULL
is	NULL
essential	NULL
for	NULL
TRAIL	NULL
(	NULL
Apo2L	NULL
)	NULL
-in-duced	NULL
activation	NULL
of	NULL
IkappaB	NULL
kinase	NULL
and	NULL
c-Jun	NULL
N-Terminal	NULL
kinase	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

2000	NULL
;	NULL
20:6638-6645	NULL
.	NULL

Orban	NULL
Z	NULL
,	NULL
Mitsiades	NULL
N	NULL
,	NULL
Burke	NULL
TR	NULL
Jr	NULL
,	NULL
Tsokos	NULL
M	NULL
,	NULL
Chrousos	NULL
GP	NULL
.	NULL

Caffeic	NULL
acid	NULL
phenethy	NULL
!	NULL

ester	NULL
induces	NULL
leukocyte	NULL
apoptosis	NULL
,	NULL
modulates	NULL
nuclear	NULL
factor-kappa	NULL
B	NULL
and	NULL
suppresses	NULL
acute	NULL
inflamma-tion	NULL
.	NULL

Neuroimmunomodulation	NULL
.	NULL

2000	NULL
;	NULL
7:99-105	NULL
.	NULL

Wang	NULL
CY	NULL
,	NULL
Cusack	NULL
JC	NULL
Jr	NULL
,	NULL
Liu	NULL
R	NULL
,	NULL
Baldwin	NULL
AS	NULL
Jr.	NULL
Control	NULL
of	NULL
inducible	NULL
chemoresistance	NULL
:	NULL
enhanced	NULL
anti-tumor	NULL
therapy	NULL
through	NULL
increased	NULL
apoptosis	NULL
by	NULL
inhibition	NULL
of	NULL
NF-kappa	NULL
B.	NULL
Nat	NULL
Med	NULL
.	NULL

1999	NULL
;	NULL
5	NULL
:	NULL
412-417	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
2001	NULL
98	NULL
:	NULL
795-804	NULL
doi:10.1182/blood.V98.3.795	NULL
TRAIL/Apo2L	NULL
ligand	NULL
selectively	NULL
induces	NULL
apoptosis	NULL
and	NULL
overcomes	NULL
drug	NULL
resistance	NULL
in	NULL
multiple	NULL
myeloma	NULL
:	NULL
therapeutic	NULL
applications	NULL
A	NULL
TY	NULL
O	NULL
0C	NULL
,	NULL
f	NULL
ghURIC	NULL
ANA	NULL
a	NULL
'	NULL
%	NULL
:	NULL
r	NULL
)	NULL
...	NULL
3\	NULL
®	NULL
``	NULL
Pion	NULL
(	NULL
@	NULL
0	NULL
Constantine	NULL
S.	NULL
Mitsiades	NULL
,	NULL
Steven	NULL
P.	NULL
Treon	NULL
,	NULL
Nicholas	NULL
Mitsiades	NULL
,	NULL
Yoshihito	NULL
Shima	NULL
,	NULL
Paul	NULL
Richardson	NULL
,	NULL
Robert	NULL
Schlossman	NULL
,	NULL
Teru	NULL
Hideshima	NULL
and	NULL
Kenneth	NULL
C.	NULL
Anderson	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/98/3/795.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Apoptosis	NULL
(	NULL
747	NULL
articles	NULL
)	NULL
Neoplasia	NULL
(	NULL
4182	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

